<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d7" for="edge" attr.name="order" attr.type="long" />
  <key id="d6" for="edge" attr.name="source_id" attr.type="string" />
  <key id="d5" for="edge" attr.name="description" attr.type="string" />
  <key id="d4" for="edge" attr.name="weight" attr.type="double" />
  <key id="d3" for="node" attr.name="clusters" attr.type="string" />
  <key id="d2" for="node" attr.name="source_id" attr.type="string" />
  <key id="d1" for="node" attr.name="description" attr.type="string" />
  <key id="d0" for="node" attr.name="entity_type" attr.type="string" />
  <graph edgedefault="undirected">
    <node id="&quot;AMERICAN DIABETES ASSOCIATION (ADA)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The ADA is an organization involved in publishing a report on diabetes management."&lt;SEP&gt;"The ADA is an organization that, along with the EASD, creates consensus reports on managing type 1 diabetes in adults."&lt;SEP&gt;"The American Diabetes Association is responsible for setting the Standards of Care in Diabetes, and it has a Professional Practice Committee that updates these standards regularly."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-4897d32a01ffeb7a8d01e64f36b6aa77&lt;SEP&gt;chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 9}]</data>
    </node>
    <node id="&quot;ADA PROFESSIONAL PRACTICE COMMITTEE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The ADA Professional Practice Committee is an interprofessional expert committee that updates the Standards of Care in Diabetes."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 9}]</data>
    </node>
    <node id="&quot;DIABETES CARE 2025&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Diabetes Care 2025 is the publication that outlines the pharmacologic approaches to glycemic treatment as per the Standards of Care in Diabetes."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 8}]</data>
    </node>
    <node id="&quot;THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"The DCCT is a landmark trial that demonstrated the benefits of intensive insulin therapy in reducing A1C and improving long-term outcomes for type 1 diabetes patients."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 8}]</data>
    </node>
    <node id="&quot;INSULIN THERAPY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Insulin Therapy refers to the essential treatment for individuals with type 1 diabetes to manage absent or near-absent b-cell function and prevent severe metabolic disturbances."&lt;SEP&gt;"Insulin therapy is a critical treatment for many adults with type 2 diabetes to achieve and maintain glycemic goals and for acute illness or other situations."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 28}]</data>
    </node>
    <node id="&quot;INSULIN INFUSION&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Insulin Infusion involves continuous subcutaneous administration of insulin, which is a method used to provide intensive insulin replacement for individuals with type 1 diabetes."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
    </node>
    <node id="&quot;CONTINUOUS GLUCOSE MONITORING&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Continuous Glucose Monitoring is recommended for adults with type 1 diabetes to improve glycemic outcomes and quality of life."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 28}]</data>
    </node>
    <node id="&quot;A1C&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"A1C is a measure of blood glucose levels used to determine the effectiveness of diabetes treatment."&lt;SEP&gt;"A1C is a measure of blood sugar levels over the past two to three months, used to indicate the effectiveness of diabetes management."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 8}]</data>
    </node>
    <node id="&quot;HYPOGLYCEMIA&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Hypoglycemia is a condition characterized by abnormally low blood glucose levels, a significant care consideration for diabetes management."&lt;SEP&gt;"Hypoglycemia is a condition of abnormally low blood sugar levels, which treatment strategies like CSII and insulin analogs aim to reduce."&lt;SEP&gt;"Hypoglycemia is a condition where blood sugar levels drop too low, posing risks especially for individuals with advanced CKD."&lt;SEP&gt;"Hypoglycemia is a risk associated with intensive insulin therapy, where blood sugar levels drop too low."&lt;SEP&gt;"Hypoglycemia refers to low blood sugar levels, which can be a side effect of diabetes treatment and requires careful management."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 6}]</data>
    </node>
    <node id="&quot;AUTOMATED INSULIN DELIVERY SYSTEMS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Automated Insulin Delivery Systems are recommended for all adults with type 1 diabetes to help manage glycemic levels."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
    </node>
    <node id="&quot;GLUCOSE MONITORING&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Glucose Monitoring refers to the practice of regularly checking blood sugar levels using various methods to manage diabetes."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
    </node>
    <node id="&quot;MICROVASCULAR COMPLICATIONS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Microvascular Complications are health issues related to small blood vessels that can occur due to diabetes, often reduced by effective diabetes management."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
    </node>
    <node id="&quot;MACROVASCULAR COMPLICATIONS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Macrovascular Complications refer to diseases of large blood vessels that can result from diabetes, reduced through intensive glycemic management."</data>
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
    </node>
    <node id="&quot;TYPE 1 DIABETES&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Type 1 Diabetes is a chronic condition managed by insulin and other treatments, often accompanied by challenges like hypoglycemia."&lt;SEP&gt;"Type 1 Diabetes is a chronic condition managed through insulin and adjunctive therapies like Pramlintide, Metformin, and Liraglutide."&lt;SEP&gt;"Type 1 Diabetes is a chronic condition that necessitates insulin treatment to manage blood sugar levels. The document discusses treatment plans for managing this condition, including various types of insulin and delivery methods."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9&lt;SEP&gt;chunk-fb858d4e362841ba84f2a63603216725&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;INSULIN PUMP THERAPY&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Insulin Pump Therapy is a method of insulin delivery that simulates normal insulin secretion and includes hybrid closed-loop and open-loop systems. It offers flexibility and higher time-in-range rates."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 25}]</data>
    </node>
    <node id="&quot;CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"CSII via pump therapy helps lower A1C levels and reduces the risk of severe hypoglycemia compared to multiple daily injections."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 25}]</data>
    </node>
    <node id="&quot;MULTIPLE DAILY INJECTIONS (MDI)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"MDI is a treatment plan involving long-acting and rapid-acting insulins, providing flexibility in meal timing but requiring multiple daily injections."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;BASAL INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Basal Insulin is a component of insulin replacement plans that includes NPH insulin and long-acting insulin analogs, used for maintaining stable blood glucose levels throughout the day."&lt;SEP&gt;"Basal Insulin is a long-acting insulin used to manage glucose levels over a 24-hour period in diabetes treatment."&lt;SEP&gt;"Basal insulin is a long-acting insulin used to manage blood glucose levels, particularly effective overnight and between meals."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-fb858d4e362841ba84f2a63603216725&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 20}]</data>
    </node>
    <node id="&quot;RAPID-ACTING INSULIN ANALOGS (RAA)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"RAA are insulins with a quicker onset and shorter duration of action, used for mealtime and correction doses in insulin therapy."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;INHALED HUMAN INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Inhaled Human Insulin is a rapid-acting form of insulin that peaks quickly and has a shortened duration when compared to RAA."&lt;SEP&gt;"Inhaled Human Insulin is an alternative administration route for insulin with faster onset and shorter duration compared to injectable insulins, contraindicated for individuals with certain lung conditions."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134&lt;SEP&gt;chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 24}]</data>
    </node>
    <node id="&quot;INTERCHANGEABLE BIOSIMILARS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Interchangeable Biosimilars are insulin products that offer similar therapeutic effects as branded analogs and could impact insulin accessibility and cost."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
    </node>
    <node id="&quot;QUALITY OF LIFE IMPROVEMENT&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Quality of Life Improvement refers to the enhanced well-being of patients using CSII compared to multiple daily injections, especially concerning fear of hypoglycemia and diabetes distress."</data>
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d3">[{"level": 0, "cluster": 6}]</data>
    </node>
    <node id="&quot;HOLT ET AL.&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Holt et al. are authors cited in the context of research related to glycemic treatment."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
    </node>
    <node id="&quot;DONISLECEL-JUJN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Donislecel-jujn is the first allogeneic islet cell therapy approved in 2023 for treatment of adults with type 1 diabetes who struggle with severe hypoglycemia."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
    </node>
    <node id="&quot;U.S.&quot;">
      <data key="d0">"GEO"</data>
      <data key="d1">"The U.S. is a geographical location mentioned where allogenic islet transplantation is regulated as a cell therapy."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
    </node>
    <node id="&quot;INSULIN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Insulin is a hormone necessary for glucose management, critically used in managing diabetes, particularly when other medications are less effective."&lt;SEP&gt;"Insulin is a hormone therapy used to manage blood sugar levels in individuals with diabetes, particularly when other medications are insufficient."&lt;SEP&gt;"Insulin is a medication used in various forms for glycemic treatment, including injections, pumps, and inhalation, to manage diabetes."&lt;SEP&gt;"Insulin is considered for combination therapy in severe hyperglycemia, especially with catabolic features."&lt;SEP&gt;"Insulin is used to manage blood glucose levels in diabetes, with different formulations available, such as rapid-acting, short-acting, and long-acting."&lt;SEP&gt;"Insulin treatment is critical for diabetes management, with associated risks of hypoglycemia noted in patient care guidelines."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-9f27f49fbb657c452c4c12e087c59402&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-80ef4eb2154fdce1f321d0bae2fea359&lt;SEP&gt;chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 29}]</data>
    </node>
    <node id="&quot;CONTINUOUS GLUCOSE MONITORING (CGM)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Continuous Glucose Monitoring is a technology integrated into diabetes treatment plans to improve glycemic outcomes and reduce hypoglycemia."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;AUTOMATED INSULIN DELIVERY (AID)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Automated Insulin Delivery systems are advanced technologies that automatically manage insulin levels to improve glycemic control in diabetes patients."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;PANCREAS TRANSPLANTATION&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Pancreas Transplantation is a surgical treatment for type 1 diabetes to normalize glucose levels, commonly done alongside kidney transplantation."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;ISLET TRANSPLANTATION&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Islet Transplantation involves the transplantation of insulin-producing islets and is regulated differently across the world for diabetes treatment."</data>
      <data key="d2">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;PRAMLINTIDE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Pramlintide is a medication based on the naturally occurring b-cell peptide amylin, approved for use in adults with type 1 diabetes, and has shown modest reductions in A1C and weight loss."&lt;SEP&gt;"Pramlintide is a noninsulin glucose-lowering medication approved for use in adults with type 1 diabetes, based on the peptide amylin."&lt;SEP&gt;"Pramlintide is an amylin mimetic, utilized in diabetes treatment to control blood sugar levels."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-939ace7c2694328428c1ff23160b9ec9&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;METFORMIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Metformin is a commonly used first-line medication for type 2 diabetes that helps lower A1C levels and reduce glucose production by the liver."&lt;SEP&gt;"Metformin is a glucose-lowering medication, commonly used due to its cost-effectiveness, within the class of Biguanides."&lt;SEP&gt;"Metformin is a medication used as a first-line therapy for type 2 diabetes, beneficial in lowering A1C, weight neutral, and reduces cardiovascular mortality."&lt;SEP&gt;"Metformin is a medication used as a first-line treatment for type 2 diabetes, effective in reducing risks of microvascular complications and cardiovascular events."&lt;SEP&gt;"Metformin is a medication used in adults with type 1 diabetes, associated with small reductions in body weight, insulin dose, and lipid levels, but without sustainable improvement in A1C."&lt;SEP&gt;"Metformin is a medication used in type 2 diabetes management, providing neutral effects on weight but significant glucose-lowering efficacy."&lt;SEP&gt;"Metformin is a medication used to manage type 2 diabetes, noted for its efficacy and safety. It is preferred for those with CKD but does not have direct kidney benefits."&lt;SEP&gt;"Metformin is a widely used oral diabetes medication known for its glucose-lowering effect and weight neutrality."&lt;SEP&gt;"Metformin is an oral medication used as a first-line treatment for lowering blood glucose levels in type 2 diabetes."&lt;SEP&gt;"Metformin is the first-line oral agent recommended for treating alpelisib-induced hyperglycemia and for prophylactic use in prediabetes."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d&lt;SEP&gt;chunk-9f27f49fbb657c452c4c12e087c59402&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-80ef4eb2154fdce1f321d0bae2fea359&lt;SEP&gt;chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 27}]</data>
    </node>
    <node id="&quot;LIRAGLUTIDE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Liraglutide is a GLP-1 receptor agonist applied in diabetes treatment for controlling blood sugar levels."&lt;SEP&gt;"Liraglutide is a GLP-1 receptor agonist in subcutaneous form that provides cardiovascular and kidney benefits."&lt;SEP&gt;"Liraglutide is a GLP-1 receptor agonist with potential benefits in glucose management for people with CKD."&lt;SEP&gt;"Liraglutide is a glucagon-like peptide 1 receptor agonist assessed in clinical trials for type 1 diabetes, showing modest A1C reductions, decreases in weight, and reductions in insulin doses."&lt;SEP&gt;"Liraglutide is a glucose-lowering agent that also aids weight loss, aimed at managing type 2 diabetes."</data>
      <data key="d2">chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 23}]</data>
    </node>
    <node id="&quot;SGLT2 INHIBITOR&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"SGLT2 inhibitors are recommended for adults with type 2 diabetes and heart failure, used for glycemic management and prevention of HF hospitalizations."</data>
      <data key="d2">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;GLP-1 RA&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) is a class of drugs used to manage type 2 diabetes by lowering blood glucose levels and potentially providing cardiovascular and kidney benefit."&lt;SEP&gt;"GLP-1 RA (Glucagon-like peptide-1 receptor agonists) are used in combination with other therapies to improve glycemic control and reduce weight in diabetes management."&lt;SEP&gt;"GLP-1 RA is recommended for its proven cardiovascular benefits in diabetes management."&lt;SEP&gt;"GLP-1 RA stands for glucagon-like peptide 1 receptor agonist, a class of medications used for lowering A1C levels in individuals with diabetes."&lt;SEP&gt;"GLP-1 RA, or glucagon-like peptide-1 receptor agonist, is a class of medication used to improve glucose control in type 2 diabetes patients by enhancing insulin secretion."&lt;SEP&gt;"GLP-1 receptor agonists are medications effective in lowering glucose levels with a low risk for hypoglycemia, and are recommended for individuals with chronic kidney disease."&lt;SEP&gt;"GLP-1 receptor agonists are recommended for adults with type 2 diabetes, exhibiting benefits for glycemic management and reduction of cardiovascular events, and used in various comorbid conditions."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 14}]</data>
    </node>
    <node id="&quot;KIDNEY TRANSPLANTATION&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Kidney Transplantation can be combined with b-cell replacement therapy in individuals with end-stage kidney disease, considering surgical risks and metabolic needs."</data>
      <data key="d2">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
    </node>
    <node id="&quot;AMYLIN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Amylin is a naturally occurring b-cell peptide involved in the development of the medication Pramlintide for type 1 diabetes."</data>
      <data key="d2">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
    </node>
    <node id="&quot;HEART FAILURE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Heart Failure, both with reduced or preserved ejection fraction, is a condition for which SGLT2 inhibitors and some GLP-1 RAs are recommended in adults with type 2 diabetes."&lt;SEP&gt;"Heart failure is a condition that might be exacerbated by certain diabetes medications like pioglitazone."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
    </node>
    <node id="&quot;CKD&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"CKD (Chronic Kidney Disease) refers to the gradual loss of kidney function over time, often considered in the context of diabetes treatment decisions."&lt;SEP&gt;"CKD stands for chronic kidney disease, a condition involving gradual loss of kidney function, which affects diabetes treatment choices."&lt;SEP&gt;"CKD, or chronic kidney disease, involves a gradual loss of kidney function over time, which can complicate diabetes management."&lt;SEP&gt;"Chronic Kidney Disease (CKD) is a condition in adults with type 2 diabetes where SGLT2 inhibitors or GLP-1 RAs are suggested to manage glycemic levels and slow disease progression."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
    </node>
    <node id="&quot;MASLD&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease) is a liver condition that may be impacted by diabetes management strategies."&lt;SEP&gt;"MASLD stands for metabolic dysfunction-associated steatotic liver disease, a liver condition related to fat buildup."&lt;SEP&gt;"MASLD, or Metabolic Associated Steatosis Liver Disease, is a condition characterized by the accumulation of fat in the liver not initiated by alcohol consumption, which is associated with obesity and diabetes."&lt;SEP&gt;"Metabolic dysfunction-associated steatotic liver disease (MASLD) in adults with type 2 diabetes and obesity is considered for treatment with GLP-1 RAs or dual GIP and GLP-1 RAs."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 22}]</data>
    </node>
    <node id="&quot;MASH&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"MASH (Metabolic Dysfunction–Associated Steatohepatitis) is a form of fatty liver disease considered in diabetes management."&lt;SEP&gt;"MASH stands for metabolic dysfunction-associated steatohepatitis and is a condition characterized by liver inflammation due to fat accumulation."&lt;SEP&gt;"MASH, metabolic dysfunction-associated steatohepatitis, is a condition associated with liver inflammation and damage due to fat accumulation."&lt;SEP&gt;"MASH, metabolic dysfunction–associated steatohepatitis, is a liver condition resulting from inflammation and fat accumulation."&lt;SEP&gt;"MASH, or Metabolic Associated Steatohepatitis, is the progression of liver disease involving inflammation and liver cell damage in addition to fat in the liver, linked with obesity and diabetes."&lt;SEP&gt;"Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition in type 2 diabetes patients, where treatments with potential benefits include GLP-1 RAs and pioglitazone."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 19}]</data>
    </node>
    <node id="&quot;TYPE 2 DIABETES&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Type 2 Diabetes is a chronic condition that affects the regulation of glucose in the body and is the focus of this glycemic treatment plan."&lt;SEP&gt;"Type 2 Diabetes is a chronic condition that affects the way the body processes blood sugar, requiring various management and treatment strategies."&lt;SEP&gt;"Type 2 Diabetes is a chronic metabolic condition that affects glucose regulation and requires careful management to prevent comorbidities."&lt;SEP&gt;"Type 2 Diabetes is managed through lifestyle changes and medications like SGLT2 inhibitors, GLP-1 RAs, and others tailored to individual patient needs."&lt;SEP&gt;"Type 2 diabetes is a chronic condition affecting the way the body processes blood sugar, typically managed through diet, exercise, and medication."&lt;SEP&gt;"Type 2 diabetes is a progressive disease that often requires combination therapy to maintain glycemic goals."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;HYPERGLYCEMIA&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Hyperglycemia refers to elevated blood glucose levels, often requiring management in individuals with type 2 diabetes."&lt;SEP&gt;"Hyperglycemia refers to high blood glucose levels, a condition that requires management in diabetes treatment."&lt;SEP&gt;"Hyperglycemia refers to high blood sugar levels, indicating unregulated diabetes that requires treatment adjustment."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 29}]</data>
    </node>
    <node id="&quot;DPP-4 INHIBITORS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"DPP-4 inhibitors are a class of diabetes medication that includes drugs like Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin, which work by enhancing insulin secretion."&lt;SEP&gt;"DPP-4 inhibitors are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4, used to prolong the active incretin levels in patients with type 2 diabetes."&lt;SEP&gt;"DPP-4 inhibitors are oral agents in diabetes management that help lower blood sugar with minimal effects on weight."&lt;SEP&gt;"DPP-4 inhibitors are oral medications for type 2 diabetes with known effects on glucose metabolism but require kidney function monitoring."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 15}]</data>
    </node>
    <node id="&quot;ASCVD&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"ASCVD (Atherosclerotic Cardiovascular Disease) is a condition that includes events such as myocardial infarction and stroke, affecting individuals with established cardiovascular disease."&lt;SEP&gt;"ASCVD stands for atherosclerotic cardiovascular disease, a condition involving narrowed arteries due to plaque buildup, which is a risk factor considered in diabetes treatment."&lt;SEP&gt;"ASCVD, or atherosclerotic cardiovascular disease, involves the buildup of fats, cholesterol, and other substances in and on artery walls."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 16}]</data>
    </node>
    <node id="&quot;SULFONYLUREAS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Sulfonylureas are a class of glucose-lowering medications that can be a lower-cost option for managing diabetes within certain contexts."&lt;SEP&gt;"Sulfonylureas are a class of medications that stimulate insulin release from the beta cells in the pancreas, used in managing type 2 diabetes."&lt;SEP&gt;"Sulfonylureas are a class of medications used to increase insulin release, with a risk of hypoglycemia possibly heightened in CKD."&lt;SEP&gt;"Sulfonylureas are a class of oral medications used to lower blood sugar in type 2 diabetes, known for potential weight gain."&lt;SEP&gt;"Sulfonylureas are compared with Metformin in terms of effectiveness for type 2 diabetes treatment."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-9f27f49fbb657c452c4c12e087c59402&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 6}]</data>
    </node>
    <node id="&quot;MEGLITINIDES&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Meglitinides are a class of diabetes medication including drugs like Nateglinide and Repaglinide, known for stimulating insulin release to control blood sugar levels."&lt;SEP&gt;"Meglitinides are a class of oral diabetes medications that help control blood sugar levels by stimulating the pancreas to release insulin."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;IMMEDIATE-RELEASE FORM&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Immediate-release form of Metformin allows for twice-daily dosing."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;EXTENDED-RELEASE FORM&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Extended-release form of Metformin allows for once daily dosing to mitigate side effects."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"DPP-4 inhibitors are less effective than Metformin for lowering A1C and weight as monotherapy."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;GASTROINTESTINAL INTOLERANCE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Gastrointestinal intolerance is a side effect of Metformin, involving bloating, abdominal discomfort, and diarrhea."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 27}]</data>
    </node>
    <node id="&quot;LACTIC ACIDOSIS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Lactic acidosis is a rare but serious complication associated with high levels of Metformin, especially in people with low eGFR."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 27}]</data>
    </node>
    <node id="&quot;VITAMIN B12 DEFICIENCY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Vitamin B12 deficiency can occur as a side effect of Metformin use and requires monitoring."&lt;SEP&gt;"Vitamin B12 deficiency is a risk associated with Metformin use, which can worsen symptoms of neuropathy."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 27}]</data>
    </node>
    <node id="&quot;HEALTHY LIFESTYLE BEHAVIORS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Healthy Lifestyle Behaviors are advocated to manage diabetes along with medications."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;CARDIOVASCULAR AND KIDNEY RISK REDUCTION&quot;">
      <data key="d0">"GEO"</data>
      <data key="d1">"This involves strategies for managing diabetes to prevent cardiovascular and kidney complications in high-risk patients."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;EGFR&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"eGFR (estimated Glomerular Filtration Rate) is a measure used to assess kidney function and is important in determining the efficacy of diabetes treatments."&lt;SEP&gt;"eGFR (estimated glomerular filtration rate) is a measure of kidney function that impacts the use of Metformin and SGLT2i."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;SGLT2I&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"SGLT2i (Sodium–Glucose Cotransporter 2 Inhibitor) is a class of medications used to manage type 2 diabetes, known for cardiovascular and kidney outcomes benefits."&lt;SEP&gt;"SGLT2i is used for its cardiovascular and kidney protective benefits in diabetes management."&lt;SEP&gt;"SGLT2i refers to sodium-glucose cotransporter 2 inhibitors, a class of medications used to manage type 2 diabetes."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 14}]</data>
    </node>
    <node id="&quot;POLYURIA&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Polyuria, or frequent urination, is a symptom associated with hyperglycemia."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;POLYDIPSIA&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Polydipsia is excessive thirst, often a symptom of hyperglycemia."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;CATABOLISM&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Catabolism refers to the breakdown of complex molecules, which can occur in uncontrolled diabetes, leading to weight loss."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;COMBINATION THERAPY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Combination Therapy is the use of multiple medications to manage diabetes effectively."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;ACE INHIBITORS (ACEI)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"ACE inhibitors are medications often used in combination to manage diabetes and protect kidney function."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;ANGIOTENSIN RECEPTOR BLOCKERS (ARB)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"ARBs are medications used to manage diabetes and prevent kidney damage, especially when combined with other drugs."</data>
      <data key="d2">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
    </node>
    <node id="&quot;SEMAGLUTIDE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Semaglutide is a GLP-1 receptor agonist reported to have beneficial effects on cardiovascular disease, mortality, and kidney outcomes for people with chronic kidney disease."&lt;SEP&gt;"Semaglutide is a medication classified under GLP-1 RAs, known for high efficacy in weight loss and glucose lowering in individuals with type 2 diabetes."&lt;SEP&gt;"Semaglutide is a medication with high efficacy in glucose lowering and weight loss for type 2 diabetes management."&lt;SEP&gt;"Semaglutide is a member of the GLP-1 RAs used for effective management of blood sugar in diabetes patients."&lt;SEP&gt;"Semaglutide, available in both subcutaneous and oral formulations, is a GLP-1 receptor agonist with cardiovascular and kidney benefits."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 21}]</data>
    </node>
    <node id="&quot;DULAGLUTIDE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Dulaglutide is a GLP-1 RA medication used in treating type 2 diabetes, noted for high glucose-lowering efficacy especially at high doses."&lt;SEP&gt;"Dulaglutide is a GLP-1 RA medication used to improve blood sugar control in diabetes patients."&lt;SEP&gt;"Dulaglutide is a GLP-1 receptor agonist available in subcutaneous form offering cardiovascular and potential kidney benefits."&lt;SEP&gt;"Dulaglutide is a medication used to lower glucose levels with a positive effect on weight, used in type 2 diabetes treatment."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 21}]</data>
    </node>
    <node id="&quot;TIRZEPATIDE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Tirzepatide is a dual GIP and GLP-1 receptor agonist, for which no dedicated kidney outcomes studies have been published yet."&lt;SEP&gt;"Tirzepatide is a medication that targets GIP and GLP-1 receptors, utilized for diabetes management."&lt;SEP&gt;"Tirzepatide is a medication used for weight loss and glucose lowering with very high efficacy in individuals with type 2 diabetes."&lt;SEP&gt;"Tirzepatide is a medication used to lower glucose levels and support weight loss, especially effective for individuals with type 2 diabetes."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 21}]</data>
    </node>
    <node id="&quot;PIOGLITAZONE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Pioglitazone is a Thiazolidinedione drug used for improving blood sugar control in diabetes patients."&lt;SEP&gt;"Pioglitazone is a medication for type 2 diabetes, offering high glucose-lowering efficacy and potential benefits in metabolic conditions."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;MACE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"MACE (Major Adverse Cardiovascular Events) encompasses endpoints such as cardiovascular death, myocardial infarction, and stroke."&lt;SEP&gt;"MACE stands for major adverse cardiovascular events and is a term used in cardiovascular health studies."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 16}]</data>
    </node>
    <node id="&quot;DSMES&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"DSMES (Diabetes Self-Management Education and Support) provides resources for individuals with diabetes to enhance self-efficacy and achieve treatment goals."&lt;SEP&gt;"DSMES stands for Diabetes Self-Management Education and Support, an empowerment model focusing on teaching individuals to manage their diabetes effectively."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 22}]</data>
    </node>
    <node id="&quot;CVD&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"CVD (Cardiovascular Disease) involves conditions affecting the heart and blood vessels, essential in diabetes treatment decisions."&lt;SEP&gt;"CVD stands for cardiovascular disease, which is an important consideration when selecting diabetes treatments for individuals."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 16}]</data>
    </node>
    <node id="&quot;ACEI&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"ACEi (Angiotensin-Converting Enzyme Inhibitor) is a medication class used to treat high blood pressure, with implications for diabetes treatment."</data>
      <data key="d2">chunk-0328b0f6d78fc747e105127ef9112362</data>
    </node>
    <node id="&quot;DAVIES ET AL.&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Davies et al. are authors or researchers whose work has been adapted or referenced in the context of diabetes treatment."&lt;SEP&gt;"Davies et al. refers to the authors of a study or paper referenced in the document."</data>
      <data key="d2">chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 14}]</data>
    </node>
    <node id="&quot;MI&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"MI stands for myocardial infarction, commonly known as a heart attack, a serious cardiovascular event."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 15}]</data>
    </node>
    <node id="&quot;SDOH&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"SDOH refers to social determinants of health, which are conditions influencing health outcomes."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;T2D&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"T2D stands for type 2 diabetes, a chronic condition affecting glucose metabolism."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;SGLT2 INHIBITORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"SGLT2 Inhibitors are a class of medication used to lower blood glucose by preventing glucose reabsorption in the kidneys."&lt;SEP&gt;"SGLT2 inhibitors are a class of diabetes medication including drugs like Bexagliflozin, Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin, known for helping the kidneys remove glucose from the bloodstream."&lt;SEP&gt;"SGLT2 inhibitors are a class of drugs recommended for people with type 2 diabetes and chronic kidney disease, shown to have beneficial effects on slowing progression of CKD and cardiovascular outcomes."&lt;SEP&gt;"SGLT2 inhibitors are oral medications that help lower blood glucose levels and offer cardiovascular and kidney benefits."&lt;SEP&gt;"SGLT2 inhibitors are oral medications that lower blood glucose and may aid weight management in type 2 diabetes."</data>
      <data key="d2">chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 15}]</data>
    </node>
    <node id="&quot;GLP-1 RAS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"GLP-1 RAs, including drugs like semaglutide, are used to lower blood glucose levels and offer cardiovascular and kidney benefits."&lt;SEP&gt;"GLP-1 RAs, or glucagon-like peptide 1 receptor agonists, are diabetes medications including Dulaglutide, Exenatide, Liraglutide, and Semaglutide, used to improve blood sugar control."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 16}]</data>
    </node>
    <node id="&quot;DUAL GIP AND GLP-1 RA&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Dual GIP and GLP-1 RA refers to a class of medication like Tirzepatide, targeting dual hormone receptors for enhanced blood sugar management in diabetes."&lt;SEP&gt;"Dual GIP and GLP-1 RA refers to a type of injectable medication under investigation for managing diabetes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;EFFECT ON HF&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Effect on HF refers to the impact on heart failure outcomes, as assessed for different medications."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;PROGRESSION OF CKD&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Progression of CKD refers to the advancement of chronic kidney disease and is evaluated in relation to different treatments."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;CANAGLIFLOZIN&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Canagliflozin is an SGLT2 inhibitor drug facilitating glucose elimination via the kidneys to manage diabetes."&lt;SEP&gt;"Canagliflozin is an SGLT2 inhibitor medication that provides cardiovascular and kidney benefits."&lt;SEP&gt;"Canagliflozin is an SGLT2 inhibitor shown to have beneficial effects on CKD progression and cardiovascular outcomes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b</data>
    </node>
    <node id="&quot;EMPAGLIFLOZIN&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Empagliflozin is an SGLT2 inhibitor that has demonstrated benefits in slowing CKD progression and improving cardiovascular outcomes."&lt;SEP&gt;"Empagliflozin is an SGLT2 inhibitor with noted cardiovascular and kidney benefits."&lt;SEP&gt;"Empagliflozin, an SGLT2 inhibitor, aids in the removal of glucose by the kidneys for better diabetes management."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 15}]</data>
    </node>
    <node id="&quot;DAPAGLIFLOZIN&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Dapagliflozin is a part of the SGLT2 inhibitors class, used in diabetes treatment by promoting renal glucose clearance."&lt;SEP&gt;"Dapagliflozin is an SGLT2 inhibitor effective in slowing the progression of CKD and favorable cardiovascular outcomes."&lt;SEP&gt;"Dapagliflozin is an SGLT2 inhibitor that provides benefits for heart failure and kidney disease management."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b</data>
    </node>
    <node id="&quot;ERTUGLIFLOZIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Ertugliflozin is a drug included in the SGLT2 inhibitors category, assisting in glucose removal for diabetes management."&lt;SEP&gt;"Ertugliflozin is one of the SGLT2 inhibitors used for diabetes management and related cardiovascular benefits."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;EXENATIDE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Exenatide is a GLP-1 RA available in a weekly injection form, providing glucose-lowering benefits."&lt;SEP&gt;"Exenatide is a glucagon-like peptide 1 receptor agonist, contributing to blood sugar management in diabetes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;LIXISENATIDE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Lixisenatide is a GLP-1 RA that assists in glucose management for individuals with type 2 diabetes."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;SITAGLIPTIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Sitagliptin is a DPP-4 inhibitor that requires dose adjustment based on kidney function."&lt;SEP&gt;"Sitagliptin is a drug categorized as a DPP-4 inhibitor, enhancing insulin secretion and glucose control."&lt;SEP&gt;"Sitagliptin is a medication used in the treatment of type 2 diabetes, with dose adjustments required based on kidney function."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;SAXAGLIPTIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Saxagliptin belongs to the DPP-4 inhibitors class, used to aid in better blood sugar control in diabetes."&lt;SEP&gt;"Saxagliptin is a DPP-4 inhibitor with potential cardiovascular risks, requiring kidney function-based dose adjustments."&lt;SEP&gt;"Saxagliptin is a medication for managing type 2 diabetes, potentially linked to risk but used with dose adjustments dependent on kidney function."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;ALOGLIPTIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Alogliptin is a DPP-4 inhibitor that necessitates dose adjustments according to kidney function."&lt;SEP&gt;"Alogliptin is a drug prescribed for type 2 diabetes, requiring dosage modifications according to renal function."&lt;SEP&gt;"Alogliptin is part of the DPP-4 inhibitors category, helping to enhance insulin secretion for better blood sugar management."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;LINAGLIPTIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Linagliptin is a DPP-4 inhibitor medication used in diabetes for improving insulin secretion and managing blood glucose levels."&lt;SEP&gt;"Linagliptin is a DPP-4 inhibitor that does not require dose adjustment based on kidney function."&lt;SEP&gt;"Linagliptin is used in treating type 2 diabetes and does not require dose adjustments."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;GI SIDE EFFECTS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"GI side effects refer to gastrointestinal discomfort or issues that may occur with certain diabetes medications."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;THYROID C-CELL TUMORS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Thyroid C-cell tumors are identified in rodent studies with GLP-1 RAs, though human relevance is not determined."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;PANCREATITIS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Pancreatitis is a condition of pancreas inflammation and potential risk associated with some diabetes treatments."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;GALLBLADDER DISEASE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Gallbladder disease is a risk to evaluate when using certain medications for individuals with type 2 diabetes."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;DIABETIC RETINOPATHY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Diabetic retinopathy is an eye condition associated with diabetes, necessitating monitoring in high-risk individuals."</data>
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
    </node>
    <node id="&quot;U.S. FOOD AND DRUG ADMINISTRATION&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The FDA is a regulatory body in the United States that provides warnings and approvals regarding pharmaceuticals and medical treatments."&lt;SEP&gt;"The U.S. Food and Drug Administration is a government agency responsible for protecting public health by ensuring the safety and efficacy of drugs, including providing drug safety communications."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;CKD, CHRONIC KIDNEY DISEASE&quot;">
      <data key="d0">"GEO"</data>
      <data key="d1">"CKD is a condition affecting kidney function and necessitates careful consideration of medication dosages."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;FDA SPECIAL WARNING&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"The FDA has issued a special warning about increased cardiovascular mortality risk with certain older sulfonylurea medications."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 18}]</data>
    </node>
    <node id="&quot;DIABETES CARE VOLUME 48&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"This publication discusses various treatment approaches and guidelines for managing glycemic levels in diabetes."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"MASH is a liver disease that can be associated with metabolic dysfunctions, impacting diabetes treatment decisions."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;BLADDER CANCER&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Bladder cancer is a condition considered when prescribing pioglitazone, as it should not be used in active cases or with caution in those with a prior history."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST (GLP-1 RA)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"GLP-1 RAs are medications used in the management of type 2 diabetes, considered if A1C goals are not met."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;SODIUM–GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"SGLT2 inhibitors are a class of medications used in type 2 diabetes treatment, effective in lowering blood sugar levels."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;DIABETIC KETOACIDOSIS (DKA)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"DKA is a serious complication of diabetes that is considered in the management and treatment of the disease."&lt;SEP&gt;"DKA is a serious diabetes complication where the body produces excess blood acids (ketones) due to lack of insulin."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;TYPE 2 DIABETES (T2D)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"T2D is a chronic condition characterized by insulin resistance and high blood glucose levels, requiring careful management."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;GLYBURIDE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Glyburide is a second-generation sulfonylurea used to manage blood sugar levels in type 2 diabetes, not recommended in CKD."&lt;SEP&gt;"Glyburide is another Sulfonylureas (2nd generation) medication, utilized in controlling blood sugar in diabetes patients."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;GLIPIZIDE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Glipizide is a Sulfonylureas (2nd generation) drug, available in immediate and extended-release forms, used in diabetes management."&lt;SEP&gt;"Glipizide is a sulfonylurea used in diabetes management, initiated conservatively in patients with renal impairments."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;GLIMEPIRIDE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Glimepiride is a medication belonging to the class of Sulfonylureas (2nd generation), used to control blood sugar levels in diabetes."&lt;SEP&gt;"Glimepiride is a sulfonylurea medication for diabetes, shown to be cardiovascularly safe in some studies."&lt;SEP&gt;"Glimepiride is a sulfonylurea used in diabetes management, though it did not prevent CKD development when added to metformin in studies."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0&lt;SEP&gt;chunk-8de930782e0a422078be5f8ebc18884b</data>
    </node>
    <node id="&quot;NPH INSULIN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"NPH insulin is an intermediate-acting form of insulin used in diabetes management, often adjusted based on A1C levels and hypoglycemia risk."</data>
      <data key="d2">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
    </node>
    <node id="&quot;PRANDIAL INSULIN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Prandial Insulin is used to manage glucose levels around meal times to address postprandial glucose excursions."&lt;SEP&gt;"Prandial insulin is a fast-acting insulin given at meals to control postprandial blood glucose spikes."&lt;SEP&gt;"Prandial insulin is administered at meal times to manage blood sugar excursions, with dosing tailored to individual needs."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 20}]</data>
    </node>
    <node id="&quot;NPH&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"NPH is a type of basal insulin used in diabetes management and is described in multiple dosing strategies."</data>
      <data key="d2">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 14}]</data>
    </node>
    <node id="&quot;FPG&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"FPG stands for Fasting Plasma Glucose, a test measuring blood sugar levels after fasting and used to manage diabetes."</data>
      <data key="d2">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
    </node>
    <node id="&quot;HF&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"HF stands for heart failure, a condition where the heart does not pump blood effectively, considered in managing diabetes treatment for high-risk patients."</data>
      <data key="d2">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
    </node>
    <node id="&quot;GRADE TRIAL&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"The GRADE trial is a secondary analysis study that explored the effectiveness of diabetes medications on CKD development, excluding SGLT2 inhibitors."</data>
      <data key="d2">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 27}]</data>
    </node>
    <node id="&quot;CHRONIC KIDNEY DISEASE (CKD)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A long-term condition characterized by a gradual loss of kidney function over time, impacting glucose-lowering therapy focus."</data>
      <data key="d2">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 31}]</data>
    </node>
    <node id="&quot;EGFR (ESTIMATED GLOMERULAR FILTRATION RATE)&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"eGFR is a measure of kidney function used to guide treatment decisions and medication suitability in CKD patients."</data>
      <data key="d2">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 31}]</data>
    </node>
    <node id="&quot;INSULIN GLARGINE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Insulin Glargine is a long-acting form of insulin used to manage blood sugar levels in individuals with diabetes."</data>
      <data key="d2">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 29}]</data>
    </node>
    <node id="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"This group includes individuals with elevated blood sugar levels due to insulin resistance, often associated with obesity, and at risk for conditions like MASLD and MASH."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 19}]</data>
    </node>
    <node id="&quot;U-100 GLARGINE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"U-100 glargine is a long-acting basal insulin analog used to manage blood glucose levels, known for reducing hypoglycemia risk."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
    </node>
    <node id="&quot;DEGLUDEC&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Degludec is a long-acting insulin available in vials and prefilled pens in different concentrations."&lt;SEP&gt;"Degludec is a longer-acting basal insulin analog that offers reduced risk of nocturnal hypoglycemia."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;INSULINS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Insulins are medications used in diabetes management to lower blood glucose levels, with varying effects on weight and dosing strategies."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 19}]</data>
    </node>
    <node id="&quot;THIAZOLIDINEDIONES&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Thiazolidinediones are oral diabetes medications that improve insulin sensitivity but may cause weight gain."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
    </node>
    <node id="&quot;DOPAMINE AGONISTS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Dopamine agonists are medications that influence dopamine receptors, sometimes used in managing diabetes for weight benefits."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
    </node>
    <node id="&quot;BILE ACID SEQUESTRANTS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Bile acid sequestrants are medications that can aid in lipid management and have modest effects on blood glucose and weight."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
    </node>
    <node id="&quot;Α-GLUCOSIDASE INHIBITORS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"α-Glucosidase inhibitors are a type of diabetes medication including drugs like Acarbose and Miglitol, used to slow carbohydrate absorption and manage blood sugar."&lt;SEP&gt;"α-glucosidase inhibitors are diabetes medications that delay carbohydrate absorption with modest weight effects."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;PREMIXED INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Premixed Insulin refers to a simple and convenient way of administering insulin, typically in two doses per day, often viewed as a less costly alternative to insulin analogs."&lt;SEP&gt;"Premixed insulin is a combination of intermediate- and fast-acting insulin, providing day-long glucose control for type 2 diabetes."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a&lt;SEP&gt;chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 20}]</data>
    </node>
    <node id="&quot;OBESITY&quot;">
      <data key="d0">"GEO"</data>
      <data key="d1">"Obesity is a medical condition characterized by excess body fat, impacting health and increasing the risk of metabolic diseases such as type 2 diabetes."</data>
      <data key="d2">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 19}]</data>
    </node>
    <node id="&quot;U-500 REGULAR INSULIN&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"U-500 Regular Insulin is a concentrated insulin preparation, five times more concentrated than U-100, with distinct pharmacokinetics offering a longer duration of action and potentially more suited to patients with insulin resistance."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 10}]</data>
    </node>
    <node id="&quot;U-300 GLARGINE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"U-300 Glargine is a highly concentrated form of basal insulin allowing higher dose administration per volume with prolonged duration but lower efficacy per unit compared with U-100 glargine."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 10}]</data>
    </node>
    <node id="&quot;U-200 DEGLUDEC&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"U-200 Degludec is a concentrated insulin intended to provide greater volume efficiency for higher doses, also has similar pharmacokinetics to its less concentrated counterpart."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;FEV1 TESTING&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"FEV1 Testing is a spirometry test required for individuals before and after starting inhaled insulin therapy to assess lung function."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 24}]</data>
    </node>
    <node id="&quot;DIABETES CARE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Diabetes Care appears multiple times as a journal or event associated with publishing studies and findings related to diabetes."&lt;SEP&gt;"Diabetes Care is a journal published by the American Diabetes Association, focusing on diabetes research and treatment guidelines."&lt;SEP&gt;"Diabetes Care is likely an organization involved in publishing guidelines and information on diabetes management, providing insights into insulin use, pharmacologic treatments, and cost considerations."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-4897d32a01ffeb7a8d01e64f36b6aa77&lt;SEP&gt;chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 10}]</data>
    </node>
    <node id="&quot;BASAL-PRANDIAL PLANS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Basal-Prandial Plans involve individualizing insulin administration, providing greater flexibility for people with variable meal schedules."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;INSULIN RESISTANCE&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Insulin Resistance is a condition where individuals require larger doses of insulin to maintain glucose control, often necessitating concentrated insulin preparations."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 4}, {"level": 1, "cluster": 20}]</data>
    </node>
    <node id="&quot;HIGH-DEDUCTIBLE HEALTH PLANS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"High-Deductible Health Plans are insurance plans with higher out-of-pocket costs for medical expenses, impacting diabetes glucose-lowering therapy affordability for patients."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 10}]</data>
    </node>
    <node id="&quot;CHRONIC LUNG DISEASE&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Chronic Lung Disease includes conditions like asthma and COPD and impacts the suitability of inhaled insulin due to potential contraindications."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d3">[{"level": 0, "cluster": 5}, {"level": 1, "cluster": 24}]</data>
    </node>
    <node id="&quot;OUT-OF-POCKET COSTS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Out-of-Pocket Costs refer to the expenses for medical care that aren't reimbursed by insurance, affecting diabetes medication affordability for many individuals."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;GLUCAGON&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Glucagon is a medication prescribed to individuals with diabetes to treat hypoglycemia and is available in various forms."&lt;SEP&gt;"Glucagon is a medication recommended for all individuals at high risk of hypoglycemia, crucial for emergency management of low blood glucose levels."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402&lt;SEP&gt;chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;THREE MAJOR INSULIN MANUFACTURERS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Three Major Insulin Manufacturers have implemented policies to cap insulin prices, aiming to improve affordability for patients."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;INSULIN ANALOGUES&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Insulin Analogues are modified forms of insulin designed to mimic the body’s natural insulin, often more expensive than human insulins."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;CONTINUOUS INSULIN PUMPS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Continuous Insulin Pumps are devices for insulin administration offering programmable basal and bolus settings for diabetes management."</data>
      <data key="d2">chunk-970dc1eedc28722313163911ded94134</data>
    </node>
    <node id="&quot;INDIVIDUALS WITH DIABETES&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Individuals with diabetes are those who are undergoing treatment for diabetes, potentially using insulin and glucagon, and require various medical and lifestyle considerations."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;CLINICIANS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Clinicians are healthcare professionals responsible for prescribing glucagon and assessing the diabetes management needs of individuals."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;SCHOOL PERSONNEL&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"School personnel are part of the support network for individuals with diabetes, educated to administer glucagon in emergencies."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;CAREGIVERS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Caregivers are individuals responsible for the well-being of persons with diabetes, trained to administer glucagon."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;HEALTHCARE TEAM&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The healthcare team includes pharmacists, social workers, and others involved in providing diabetes care and cost-saving strategies."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;FDA&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The FDA is a regulatory organization responsible for approving medications and ensuring their safety and efficacy."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;PRECONCEPTION PLANNING&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Preconception planning involves preparing individuals with diabetes for pregnancy by addressing glycemic goals and medication management."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;SOCIAL SERVICES PROFESSIONALS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Social services professionals work alongside clinicians and the healthcare team to reduce barriers and support diabetes management for individuals."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;COMMUNITY HEALTH WORKERS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Community health workers are involved in identifying cost-saving opportunities for medications and medical equipment for individuals with diabetes."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;PHARMACISTS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Pharmacists are members of the healthcare team who help manage diabetes treatment and identify cost-saving options for medications."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;CHEMOTHERAPY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Chemotherapy can lead to hyperglycemia in individuals, affecting diabetes treatment during cancer therapy."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;GLUCOSE-LOWERING MEDICATIONS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Glucose-lowering medications are used to manage blood sugar levels in diabetes, including metformin and other FDA-approved options."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;DIABETIC KETOACIDOSIS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Diabetic ketoacidosis is a serious complication of diabetes that individuals at risk are educated to manage and prevent."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;SGLT INHIBITORS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"SGLT inhibitors are a class of glucose-lowering medications used in diabetes treatment, which require risk management for ketoacidosis."&lt;SEP&gt;"SGLT inhibitors are a class of medications used primarily to treat type 2 diabetes, though associated with certain risks when used by those with type 1 diabetes."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402&lt;SEP&gt;chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;CHILDBEARING POTENTIAL&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Childbearing potential refers to individuals with diabetes being counseled on reproductive health and the impact of medications on pregnancy plans."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;COST-RELATED BARRIERS&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"Cost-related barriers refer to financial challenges that can impede diabetes management, requiring collective efforts to overcome."</data>
      <data key="d2">chunk-9f27f49fbb657c452c4c12e087c59402</data>
    </node>
    <node id="&quot;SULFONYLUREAS (2ND GENERATION)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Sulfonylureas (2nd generation) refers to a category of diabetes medications including drugs like Glimepiride, Glipizide, and Glyburide, commonly used to manage blood sugar levels."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 18}]</data>
    </node>
    <node id="&quot;THIAZOLIDINEDIONE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Thiazolidinedione is a class of diabetes medication, with Pioglitazone being a well-known drug in this category, helping to control blood sugar levels."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;BILE ACID SEQUESTRANT&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Bile acid sequestrants like Colesevelam are medications used to lower cholesterol and improve blood sugar levels in people with type 2 diabetes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;DOPAMINE-2 AGONIST&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Dopamine-2 agonists such as Bromocriptine are medications that affect dopamine levels, contributing to the control of blood sugar levels in diabetes patients."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;AMYLIN MIMETIC&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Amylin mimetics like Pramlintide are medications that mimic the hormone amylin, used to control blood sugar levels in diabetes patients."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"AWP or Average Wholesale Price is a pricing measure used in the pharmaceutical industry to indicate the price of drugs sold through wholesalers."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d0">"CONCEPT"</data>
      <data key="d1">"NADAC or National Average Drug Acquisition Cost is a reference price for medications reflecting the average amount paid by pharmacies to acquire drugs."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 17}]</data>
    </node>
    <node id="&quot;ACARBOSE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Acarbose is an α-Glucosidase inhibitor medication, employed to slow carbohydrate absorption and control blood sugar levels."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;MIGLITOL&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Miglitol is a medication categorized as an α-Glucosidase inhibitor, used to manage blood sugar by slowing carbohydrate digestion."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;NATEGLINIDE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Nateglinide is a Meglitinide class drug, aimed at stimulating insulin release to help control blood sugar."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;REPAGLINIDE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Repaglinide belongs to the Meglitinides class, used to stimulate insulin release and manage blood sugar levels in diabetes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;BEXAGLIFLOZIN&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Bexagliflozin is a medication under the SGLT2 inhibitors, used to help the kidneys remove excess glucose from the bloodstream."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;COLESEVELAM&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Colesevelam is a bile acid sequestrant drug used to lower cholesterol and manage blood sugar in type 2 diabetes."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;BROMOCRIPTINE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Bromocriptine is a dopamine-2 agonist used in controlling blood sugar levels in diabetes patients."</data>
      <data key="d2">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
    </node>
    <node id="&quot;IMMUNE CHECKPOINT INHIBITORS (ICIS)&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"ICIs are agents that block PD-1 and PD-L1 to suppress physiologic blocks on immune responses, leading to possible autoimmune toxicities such as diabetes."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 26}]</data>
    </node>
    <node id="&quot;ALPELISIB&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Alpelisib is a phosphatidylinositol-3-kinase (PI3K) inhibitor that can cause hyperglycemia by inhibiting PI3Kα, resulting in transient insulin resistance."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 26}]</data>
    </node>
    <node id="&quot;ASPART&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Aspart is a rapid-acting insulin product available in various forms like vials, cartridges, and prefilled pens with distinct pricing."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;GLULISINE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Glulisine is a rapid-acting insulin administered via vials and prefilled pens to manage glucose levels."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;LISPRO&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Lispro is another rapid-acting insulin with multiple formulations, including vials, cartridges, and prefilled pens."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;LISPRO-AABC&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Lispro-aabc is a variation of Lispro insulin available in vials and prefilled pens, characterized by specific pricing."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;HUMAN REGULAR INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Human Regular Insulin is a short-acting insulin available in vials and prefilled pens."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;HUMAN NPH INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Human NPH is an intermediate-acting insulin available in vials and prefilled pens."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;U-500 HUMAN REGULAR INSULIN&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"U-500 Human Regular Insulin is a concentrated insulin formulation with vials and prefilled pens."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;GLARGINE&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Glargine is a long-acting insulin offered in vials and prefilled pens, with several biosimilar/follow-on products."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;PREMIXED INSULIN PRODUCTS&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"Premixed insulin products include combinations like Aspart 70/30 and Lispro 50/50, offered in vials and prefilled pens."</data>
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
    </node>
    <node id="&quot;ASPART 70/30&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Aspart 70/30 is a premixed insulin product used for diabetes treatment, available in U-100 vial and prefilled pen forms."</data>
      <data key="d2">chunk-ae944827b39cf771aca2fcbda29e3e2e</data>
    </node>
    <node id="&quot;INCRETIN MEDICATIONS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Incretin medications, including GLP-1 RAs, GIP, and DPP-4 inhibitors, are used in treating diabetes, although they should be avoided in some individuals."</data>
      <data key="d2">chunk-ae944827b39cf771aca2fcbda29e3e2e</data>
    </node>
    <node id="&quot;DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The DCCT is a research study group involved in studying mortality and diabetes management, specifically focusing on type 1 diabetes."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) STUDY RESEARCH GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The EDIC Research Group is involved in diabetes studies, examining the effects of intensive therapy in type 1 diabetes and metabolic memory of glycemia."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The EASD is an organization collaborating with ADA on a consensus report on diabetes."&lt;SEP&gt;"The EASD, in partnership with the ADA, provides guidelines and consensus on diabetes management and studies."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 9}]</data>
    </node>
    <node id="&quot;TYPE 1 DIABETES (T1D)&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Type 1 diabetes is a chronic condition characterized by the body's inability to produce insulin, leading to high blood glucose levels."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;SECTION 6&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Section 6 refers to a specific part of diabetes management guidelines focused on glycemic goals and hypoglycemia."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;LACHIN JM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lachin JM is a researcher contributing to studies on diabetes, specifically focusing on the effects of intensive therapy in type 1 diabetes."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;NATHAN DM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Nathan DM is a researcher involved with studies concerning the management and metabolic effects of diabetes."&lt;SEP&gt;"Nathan DM is involved in research related to glycemia reduction and outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;HOLT RIG&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Holt RIG is an author of a consensus report on type 1 diabetes management, in collaboration with the ADA and EASD."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;DEVRIES JH&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"DeVries JH is a contributor to the consensus report focused on the management of type 1 diabetes."</data>
      <data key="d2">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
    </node>
    <node id="&quot;DIABETES OBES METAB 2020;22:1799–1807&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A publication or study relevant to diabetes research focusing on metabolic aspects."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;LANE W&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"One of the authors involved in the SWITCH 1 randomized clinical trial about insulin treatment for type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BAILEY TS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Another author contributing to the SWITCH 1 study regarding insulin treatment."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;GERETY G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"A contributor to the SWITCH 1 study, focused on insulin degludec versus insulin glargine."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;SWITCH 1&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"The SWITCH 1 randomized clinical trial focused on comparing insulin degludec and insulin glargine U100 for type 1 diabetes patients."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;JAMA 2017;318:33–44&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Refers to the publication of the SWITCH 1 clinical trial results."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;HOME PD&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"An author involved in the EDITION 4 clinical trial for new insulin glargine formulas."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BERGENSTAL RM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Another researcher involved in the EDITION 4 trial comparing insulin glargine units."&lt;SEP&gt;"Bergenstal RM is involved in the research on the safety and efficacy of insulin delivery through pen needles in diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633&lt;SEP&gt;chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;BOLLI GB&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bolli GB is an author contributing to research on insulin glargine's sustained effects and hypoglycemia in type 2 diabetes treatment."&lt;SEP&gt;"Co-author in the EDITION 4 trial of new insulin glargine formulations."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633&lt;SEP&gt;chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;EDITION 4&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A phase 3a, open-label clinical trial comparing different concentrations of insulin glargine in type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES CARE 2015;38:2217–2225&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication discussing the results from the EDITION 4 trial."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;YEH H-C&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"One of the authors studying the effectiveness and safety of insulin delivery methods."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BROWN TT&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to research on insulin delivery and glucose monitoring methods."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;MARUTHUR N&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher involved in the systematic review of insulin methods."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;ANN INTERN MED 2012;157:336–347&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication detailing the systematic review of insulin delivery and monitoring methods."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;SPEIGHT J&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"A researcher examining the impact of glycaemic technologies on quality of life in diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;CHOUDHARY P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"A contributor to research on glycaemic technologies and diabetes quality of life."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;WILMOT EG&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"One of the researchers studying the impact of glycaemic technologies on diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES CARE 2021;44:2225–2230&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication focusing on the effects of glycaemic technologies on diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;6-MONTH RCT: HCL VERSUS CSII CONTROL STUDY&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A study comparing hybrid closed-loop and continuous subcutaneous insulin infusion therapy."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;CASTELLANO E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lead researcher in the 6-month RCT comparing HCL and CSII therapies."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;ATTANASIO R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher involved in the RCT comparing HCL and CSII therapies."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;GIAGULLI VA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to research in the RCT on glycaemic control therapies."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES TECHNOL THER 2023;25:1–12&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication disseminating results of the RCT comparing glycemic control methods."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;MATEJKO B&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher contributing to real-life studies on basal insulin doses in type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;KUKUŁKA A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Co-contributor to insulin dosage studies for diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;KLUPA T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Involved in insulin pump clinical practice research for diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;ADV MED 2018;2018:1473160&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication of single-center experiences on basal insulin dosing."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;CENGIZ E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher involved in ISPAD clinical guidelines for diabetes treatment."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DANNE T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to ISPAD guidelines on insulin treatment for youth."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;PEDIATR DIABETES 2022;23:1277–1296&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication of ISPAD's clinical practice consensus on insulin treatment."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;KING AB&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher on basal insulin dosing for near-normal glycaemia."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES OBES METAB 2021;23:866–869&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication discussing basal insulin dosing for diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;AMERICAN DIABETES ASSOCIATION&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"American Diabetes Association is an organization focused on diabetes care and advocacy, involved in initiatives like State Insulin Copay Caps."&lt;SEP&gt;"An organization involved in publishing guidelines and research on diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633&lt;SEP&gt;chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;2025&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A future date indicating a potential focus or publication on glycemic treatment."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;THE TYPE 1 DIABETES SOURCEBOOK AUTHORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"A group of authors contributing to the comprehensive sourcebook on type 1 diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;CHIANG JL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributing author on type 1 diabetes care guidelines."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;KIRKMAN MS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to type 1 diabetes guidelines and treatment literature."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;PETERS AL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher and author in diabetes treatment and management literature."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES CARE 2014;37:2034–2054&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication of the position statement on type 1 diabetes care across the life span."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DAFNE STUDY GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"A group conducting research on insulin therapy and dietary management in diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BMJ 2002;325:746&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication discussing the DAFNE randomized controlled trial."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;ISPAD CLINICAL PRACTICE CONSENSUS GUIDELINES 2022&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A comprehensive set of guidelines for insulin treatment in children and adolescents with diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;AMERICAN DIABETES ASSOCIATION/JDRF TYPE 1 DIABETES SOURCEBOOK&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"A publication providing comprehensive information on type 1 diabetes management from the American Diabetes Association and JDRF."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;SRINIVASAN S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"A researcher involved in developing an ambulatory stabilization program for children with newly diagnosed type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;CRAIG ME&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to research on stabilization programs for newly diagnosed type 1 diabetes patients."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;MED J AUST 2004;180:277–280&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication covering the ambulatory stabilization program for children with type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;LEMIEUX L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher involved in starting subcutaneous insulin doses for newly diagnosed pediatric diabetes patients."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;PAEDIATR CHILD HEALTH 2010;15:357–362&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication discussing initial insulin dosing in pediatric populations with diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;MÜLLER UA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher focused on flexible intensive insulin therapy in adults at high risk for severe hypoglycemia and diabetic ketoacidosis."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES CARE 2006;29:2196–2199&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication on flexible intensive insulin therapy for high-risk adults."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BUILES-MONTAÑO CE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher examining efficacy and safety of carbohydrate counting for type 1 diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;J HUM NUTR DIET 2022;35:1030–1042&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication of a systematic review on dietary advice including carbohydrate counting for diabetes management."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;AL BALWI R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Contributor to research on insulin dosing algorithms for mixed meals in type 1 diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;PEDIATR DIABETES 2022;23:1635–1646&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication of a study on insulin dosing algorithms for type 1 diabetes patients."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;HOPKINS D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Researcher contributing to the DAFNE study on flexible insulin management and education in diabetes."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;DIABETES RES CLIN PRACT 2010;89:22–29&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Publication detailing long-term outcomes from the DAFNE program."</data>
      <data key="d2">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
    </node>
    <node id="&quot;BRUTTOMESSO D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bruttomesso D is a researcher involved in developing tools for adjusting insulin doses in adults with type 1 diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;DIRECNET STUDY GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The DirecNet Study Group is a research organization focusing on diabetes management with real-time continuous glucose monitoring."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;WASHINGTON&quot;">
      <data key="d0">"GEO"</data>
      <data key="d1">"Washington is a geographic location mentioned in communications related to diabetes management."&lt;SEP&gt;"Washington is the location of the FDA headquarters, from where alerts regarding pharmaceutical safety are issued."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8&lt;SEP&gt;chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;OPERATION: DULCE&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"Operation: Dulce is linked to diabetes management terms and appears in a list of various studies and trials."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;NATIONAL LIBRARY OF MEDICINE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The National Library of Medicine is a key organization providing access to biomedical information and conducts clinical research."&lt;SEP&gt;"The National Library of Medicine provides access to clinical trials and research studies such as T1-DISCO related to diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8&lt;SEP&gt;chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;ALEPPO G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Aleppo G is a researcher involved in studying the use of trend arrows in diabetes management systems."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;DIABETES RESEARCH IN CHILDREN NETWORK&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"A network that conducts studies on diabetes management in children, also known as DirecNet."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;PARISE M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Parise M is a researcher who has conducted comparative studies on insulin dose adjustment algorithms."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;PETROVSKI G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Petrovski G is involved in research on the effectiveness of meal management strategies in adolescents with type 1 diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;MINIMED 780G SYSTEM&quot;">
      <data key="d0">"TECHNOLOGY"</data>
      <data key="d1">"An advanced hybrid closed-loop system for managing glucose levels in patients with diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;REMOVAL STUDY GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The group conducting research on the cardiovascular and metabolic effects of metformin in type 1 diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;LANCET DIABETES ENDOCRINOL&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"A journal that publishes studies related to diabetes and endocrinology, including those involving liraglutide."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;TURRIN KB&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Turrin KB is a researcher studying the impact of diabetes numeracy on glycemic control in insulin pump users."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;VON HERRATH M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"von Herrath M is a researcher studying the use of anti-interleukin-21 antibodies and liraglutide in preserving beta-cell function."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;GARG SK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Garg SK is a researcher studying the efficacy and safety of semaglutide and tirzepatide in patients with type 1 diabetes."</data>
      <data key="d2">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
    </node>
    <node id="&quot;NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The National Center for Biotechnology Information is a part of the National Library of Medicine and provides access to biomedical and genomic information."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;T1-DISCO&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"T1-DISCO, or Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes, is a study focusing on the effects of the drug Semaglutide on cardiovascular outcomes in patients with type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;ADJUST-T1D&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"ADJUST-T1D, or ADJUnct Semaglutide Treatment in Type 1 Diabetes, is a clinical trial examining the use of Semaglutide as an adjunct treatment for type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;METFORMIN USE IN TYPE 2 DIABETES MELLITUS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"This refers to the research and analysis of metformin treatment and its impacts, including risks of lactic acidosis and interactions with other conditions and medications."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;RAO L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Rao L is an author who contributed to research on sodium-glucose cotransporter 2 inhibitors as an add-on therapy for type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;REN C&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ren C is a researcher involved in studies related to sodium-glucose cotransporter 2 inhibitors for treating type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;LI X&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Li X is a researcher part of a team analyzing the efficacy of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;CHEN M-B&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Chen M-B contributed to research evaluating sotagliflozin as an adjuvant therapy in type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;XU R-J&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Xu R-J is a researcher engaged in systematic reviews of sotagliflozin therapy for type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;SALPETER SR&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Salpeter SR participated in a systematic review and meta-analysis on the risk of lactic acidosis with metformin use in type 2 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;LUO S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Luo S is a researcher involved in conducting a meta-analysis on sodium-glucose cotransporter 2 inhibitors as adjunct therapy for diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;HUANG C&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Huang C is one of the researchers in the study of sodium-glucose cotransporter 2 inhibitors for type 1 diabetes mellitus."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;LI M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Li M conducted research on the effectiveness of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;LIU Z&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Liu Z is a researcher who contributed to the study on adjunct therapy using sodium-glucose cotransporter 2 inhibitors in diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;YANG X&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Yang X is involved in research assessing the impact of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin for diabetes."</data>
      <data key="d2">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
    </node>
    <node id="&quot;ADOPT STUDY GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The ADOPT Study Group is involved in a study comparing glycemic durability of different monotherapies for type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;GRADE STUDY RESEARCH GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The GRADE Study Research Group conducts research on glycemia reduction and outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;EAGLE INVESTIGATORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The EAGLE Investigators conducted a study comparing insulin glargine and liraglutide in type 2 diabetes patients."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;DUAL VIII&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"DUAL VIII is a phase 3b, open-label, randomized controlled trial studying the durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;PIONEER 4 INVESTIGATORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The PIONEER 4 Investigators are a group involved in a clinical trial focused on treating type 2 diabetes using oral semaglutide."&lt;SEP&gt;"The PIONEER 4 Investigators conducted a randomized, double-blind phase 3a trial comparing oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d&lt;SEP&gt;chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 13}]</data>
    </node>
    <node id="&quot;SUSTAIN 1&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"SUSTAIN 1 is a double-blind, randomized, placebo-controlled phase 3a trial evaluating the efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes patients."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;TSOUKAS GM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Tsoukas GM is one of the authors involved in the SUSTAIN 1 trial related to type 2 diabetes treatment."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;TSAPAS A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Tsapas A is involved in a systematic review and network meta-analysis comparing glucose-lowering drugs for type 2 diabetes."&lt;SEP&gt;"Tsapas A is the lead author of a systematic review on the efficacy of glucose-lowering medications in type 2 diabetes."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77&lt;SEP&gt;chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 12}]</data>
    </node>
    <node id="&quot;AVGERINOS I&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Avgerinos I is a researcher who contributed to a comparative effectiveness study of glucose-lowering drugs for type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;KAHN SE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kahn SE is an author involved in diabetes-related research, specifically on glycemic durability and treatment effects."&lt;SEP&gt;"Kahn SE is one of the authors involved in the SURPASS-4 study, comparing tirzepatide versus insulin glargine."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d&lt;SEP&gt;chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;BUSE JB&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Buse JB is involved in researching the effectiveness of injectable antihyperglycemic therapy in type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;PETERS A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Peters A is an author involved in research about the effectiveness of injectable treatments for type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;ABDUL-GHANI MA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Abdul-Ghani MA conducted a trial on the efficacy of initial combination therapy for new-onset diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;EDICT&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"EDICT refers to a randomized trial studying the effectiveness of initial combination therapy with metformin, pioglitazone, and exenatide in type 2 diabetes."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;ARODA VR&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Aroda VR contributed to research on insulin degludec and liraglutide therapy in type 2 diabetes."&lt;SEP&gt;"Aroda VR is an author of a trial studying the efficacy of semaglutide versus insulin glargine as an add-on to metformin in insulin-naive patients."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d&lt;SEP&gt;chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;KHUNTI K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Khunti K is involved in examining clinical inertia and its implications in diabetes care management."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;BENNETT WL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bennett WL researched the comparative effectiveness and safety of diabetes medications, including newer drugs and combinations."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;MALONEY A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Maloney A is an author of a model-based meta-analysis comparing antihyperglycemic drugs in type 2 diabetes patients."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
    </node>
    <node id="&quot;NAUCK MA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Nauck MA conducted a trial involving dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in diabetes treatment."</data>
      <data key="d2">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 11}, {"level": 2, "cluster": 30}]</data>
    </node>
    <node id="&quot;HOFF ST&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hoff ST is one of the investigators involved in the PIONEER 4 study, which compares oral semaglutide to subcutaneous liraglutide and placebo in type 2 diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 13}]</data>
    </node>
    <node id="&quot;PIONEER 4&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"PIONEER 4 is a clinical trial that examines the efficacy of oral semaglutide compared to liraglutide and placebo in type 2 diabetes patients."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 13}]</data>
    </node>
    <node id="&quot;DEL PRATO S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Del Prato S is involved in research on diabetes medication outcomes."&lt;SEP&gt;"Del Prato S is one of the investigators participating in the SURPASS-4 study, comparing tirzepatide to insulin glargine in patients with cardiovascular risks."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46&lt;SEP&gt;chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;SURPASS-4 INVESTIGATORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The SURPASS-4 Investigators are a group conducting a study on the effectiveness of tirzepatide versus insulin glargine in type 2 diabetes with increased cardiovascular risk."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;SURPASS-4&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"SURPASS-4 is a clinical trial evaluating tirzepatide against insulin glargine for people with type 2 diabetes and cardiovascular risks."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;SINGH S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Singh S co-authored a systematic review comparing glucagon-like peptide-1 receptor agonists with basal insulins in managing type 2 diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;LEVIN PA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Levin PA co-authored research reviewing the comparative effectiveness of GLP-1 receptor agonists for type 2 diabetes treatment."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;ABD EL AZIZ MS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Abd El Aziz MS contributed to a meta-analysis on the clinical effects of short or long-acting GLP-1 receptor agonists compared to insulin."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;PAVO I&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Pavo I contributed to the SURPASS-4 trial, which studied tirzepatide versus insulin glargine for patients with type 2 diabetes and heightened cardiovascular risk."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d3">[{"level": 0, "cluster": 1}]</data>
    </node>
    <node id="&quot;WRIGHT EE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Wright EE co-authored a meta-analysis of glucagon-like peptide-1 receptor agonists compared with basal insulins for treating type 2 diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;KWAN AYM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kwan AYM is a researcher involved in a systematic review comparing GLP-1 receptor agonists to basal insulins for type 2 diabetes management."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;KIM SC&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kim SC co-authored a study reviewing the effectiveness of GLP-1 receptor agonists for managing diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;GIORGINO F&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Giorgino F is a co-author of a systematic review on GLP-1 receptor agonist therapy in type 2 diabetes."&lt;SEP&gt;"Giorgino F is an author of the AWARD-2 study, comparing dulaglutide with insulin glargine in type 2 diabetes patients on metformin and glimepiride."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;BENROUBI M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Benroubi M contributed to research comparing once-weekly dulaglutide to insulin glargine in patients with type 2 diabetes mellitus."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;SUN J-H&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Sun J-H participated as a co-author in a study evaluating the safety and efficacy of dulaglutide versus insulin glargine."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;ZIMMERMANN AG&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Zimmermann AG contributed to the research on the efficacy and safety of dulaglutide in comparison with insulin glargine for diabetes."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;PECHTNER V&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Pechtner V is involved in diabetes research, specifically focusing on dulaglutide versus insulin glargine."</data>
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
    </node>
    <node id="&quot;MCGUIRE DK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"McGuire DK is an author contributing to research on the association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;SHIH WJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Shih WJ is an author contributing to research on the association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;COSENTINO F&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cosentino F is an author contributing to research on the association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;REYES-FARIAS CI&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Reyes-Farias CI is a researcher examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;REATEGUI-DIAZ M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Reategui-Diaz M is a researcher examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;ROMANI-ROMANI F&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Romani-Romani F is a researcher examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;PROKOP L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Prokop L is a researcher examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;EMPA-KIDNEY COLLABORATIVE GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Empa-Kidney Collaborative Group is a research group studying the effects of empagliﬂozin in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;CREDENCE TRIAL INVESTIGATORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"CREDENCE Trial Investigators are responsible for studying the effects of canagliﬂozin on renal outcomes in type 2 diabetes and nephropathy."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;WEXLER DJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Wexler DJ is part of the GRADE Research Group, focusing on the comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;DE BOER IH&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"de Boer IH is part of the GRADE Research Group, focusing on the comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;GHOSH A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ghosh A is part of the GRADE Research Group, focusing on the comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;GRADE RESEARCH GROUP&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"GRADE Research Group is researching the comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;NEWSOME PN&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Newsome PN is an investigator in the NN9931-4296 study on the effects of semaglutide in nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;BUCHHOLTZ K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Buchholtz K is an investigator in the NN9931-4296 study on the effects of semaglutide in nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;CUSI K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cusi K is a researcher involved in studies on liver fat reduction using tirzepatide and the effects of liraglutide in patients with nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;NN9931-4296 INVESTIGATORS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"NN9931-4296 Investigators are conducting research on subcutaneous semaglutide in nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;HERRINGTON WG&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Herrington WG is associated with the Empa-Kidney Collaborative Group, conducting research on empagliflozin in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;STAPLIN N&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Staplin N is associated with the Empa-Kidney Collaborative Group, conducting research on empagliflozin in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;WANNER C&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Wanner C is a member of the Empa-Kidney Collaborative Group, conducting research on empagliflozin in patients with chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;PERKOVIC V&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Perkovic V is associated with the CREDENCE Trial Investigators, studying the effects of canagliflozin on renal outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;JARDINE MJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jardine MJ is associated with the CREDENCE Trial Investigators, studying the effects of canagliflozin on renal outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;NEAL B&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Neal B is part of the CREDENCE Trial Investigators, responsible for studying the effects of canagliflozin on renal outcomes in type 2 diabetes."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;DAGOGO-JACK S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Dagogo-Jack S contributed to research on the glycemic efficacy and safety of ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;PRATLEY RE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Pratley RE is an author of studies assessing the efficacy and safety of SGLT2 inhibitors in diabetes and chronic kidney disease contexts."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;CHERNEY DZI&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cherney DZI is involved in research focusing on the glycemic efficacy and safety of SGLT2 inhibitor ertugliflozin in diabetes and chronic kidney disease."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;COOPER ME&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cooper ME contributed to pooled analysis of phase III trials on renal function and the effects of empagliflozin."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;TIKKANEN I&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Tikkanen I is part of research analyzing phase III trials on the influence of renal function with empagliflozin."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;BERLAND RM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Berland RM is part of research detailed in the VERTIS CV randomized trial on the efficacy of the SGLT2 inhibitor ertugliflozin."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;BELFORT R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Belfort R led a placebo-controlled trial studying the effects of pioglitazone in subjects with nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;HARRISON SA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Harrison SA contributed to research on the effects of pioglitazone in subjects with nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;BROWN K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Brown K is an author involved in research examining pioglitazone's effects in nonalcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;ARMSTRONG MJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Armstrong MJ led the LEAN Trial Team studying the safety and efficacy of liraglutide in patients with non-alcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;LEAN TRIAL TEAM&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"LEAN Trial Team is responsible for conducting a multicenter, double-blind, randomized study on liraglutide's safety and efficacy in non-alcoholic steatohepatitis."</data>
      <data key="d2">chunk-284705997e11847b0e232c90fbde9937</data>
    </node>
    <node id="&quot;KRISHNAMURTHY R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Krishnamurthy R is a researcher involved in studies related to diabetes therapy."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;SAMSON SL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Samson SL is a researcher contributing to studies on diabetes and related therapies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BAJAJ M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bajaj M is part of research studies focusing on diabetes treatment."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;ABDUL-GHANI M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Abdul-Ghani M is noted for work on combination therapy for diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MIGAHID O&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Migahid O is involved in diabetes research, particularly in combination therapies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MEGAHED A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Megahed A contributes to research on treatments for diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;DEFRONZO RA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"DeFronzo RA is a researcher specializing in diabetes and its treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;AL-OZAIRI E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Al-Ozairi E is part of diabetes research teams investigating treatment improvements."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;JAYYOUSI A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jayyousi A is a researcher involved in studies on diabetes therapy."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;LAVYNENKO O&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lavynenko O is involved in research focused on diabetes treatment effectiveness."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;ALATRACH M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Alatrach M is a researcher contributing to diabetes treatment studies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;GARVEY WT&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Garvey WT is a researcher leading studies on obesity treatment in diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;FRIAS JP&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Frias JP participates in diabetes-related obesity treatment research."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;JASTREBOFF AM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jastreboff AM is part of research into diabetes management strategies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;DAVIES M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Davies M is involved in research on diabetes drugs and their effects."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;FÆRCH L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Færch L contributes to studies on diabetes treatment efficacy."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;JEPPESEN OK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jeppesen OK is involved in diabetes-related research projects."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BONORA E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bonora E is a researcher studying the effects of diabetes medications."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;TINAHONES FJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Tinahones FJ contributes to research on diabetes treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;AHMANN AJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ahmann AJ is involved in research on the safety and efficacy of diabetes treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CAPEHORN M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Capehorn M is a researcher specializing in diabetes treatment safety."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CHARPENTIER G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Charpentier G is involved in comparative studies on diabetes medications."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;SCHAUER PR&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Schauer PR leads research on diabetes treatment comparisons."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BHATT DL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bhatt DL contributes to studies comparing diabetes treatment strategies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;KIRWAN JP&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kirwan JP is involved in diabetes treatment research."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BLONDE L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Blonde L is a researcher examining insulin titration methods."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MERILAINEN M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Merilainen M contributes to research on diabetes management techniques."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;KARWE V&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Karwe V is involved in diabetes research, particularly around insulin use."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;RASKIN P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Raskin P participates in studies on diabetes and treatment approaches."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;PORCELLATI F&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Porcellati F is a researcher studying insulin pharmacodynamics."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;LUCIDI P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lucidi P contributes to research on insulin and diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CIOLI P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cioli P is part of research into the effects of insulin on diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;WANG Z&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Wang Z is involved in research focused on insulin and diabetes treatment."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;HEDRINGTON MS&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hedrington MS contributes to diabetes treatment efficacy studies."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;SEMLITSCH T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Semlitsch T offers valuable insights into the comparative efficacy of insulin therapies in adults with type 2 diabetes."&lt;SEP&gt;"Semlitsch T participates in research on insulin therapy for diabetes management."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;ENGLER J&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Engler J contributes to reviews on diabetes treatment options."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;SIEBENHOFER A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Siebenhofer A contributes to the research field through reviews comparing insulin therapies, particularly focusing on diabetes."&lt;SEP&gt;"Siebenhofer A is involved in diabetes management research."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;JEITLER K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jeitler K is acclaimed for their role in comparing the effectiveness of different insulin treatments in type 2 diabetes."&lt;SEP&gt;"Jeitler K participates in studies comparing insulin types for diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BERGHOLD A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Berghold A contributes to research on insulin therapies for diabetes."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;RUSSELL-JONES D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Russell-Jones D is involved in studies comparing diabetes insulin treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;GALL M-A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Gall M-A contributes to diabetes research focusing on insulin efficacy."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;NIEMEYER M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Niemeyer M is involved in meta-analyses of diabetes medication."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;DIAMANT M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Diamant M is a researcher studying the effects of diabetes treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MEHTA R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Mehta R contributes to practical guidance on diabetes treatment."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;GOLDENBERG R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Goldenberg R participates in research on diabetes management."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;KATSELNIK D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Katselnik D is involved in diabetes treatment research."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;KURITZKY L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kuritzky L contributes to studies on diabetes and insulin use."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MAIORINO MI&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Maiorino MI is a researcher involved in insulin efficacy studies."&lt;SEP&gt;"Maiorino MI is an author involved in research on insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CHIODINI P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Chiodini P contributes to diabetes research projects."&lt;SEP&gt;"Chiodini P is a co-author in the systematic review and meta-analysis of the combination therapy for type 2 diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;BELLASTELLA G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bellastella G is a co-author contributing to the research on insulin and GLP-1 receptor agonists in type 2 diabetes."&lt;SEP&gt;"Bellastella G participates in studies on insulin and diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CAPUANO A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Capuano A is a co-author in the systematic review focused on insulin and GLP-1 receptor therapies in type 2 diabetes."&lt;SEP&gt;"Capuano A is involved in diabetes and insulin research."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;ESPOSITO K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Esposito K contributes to diabetes treatment efficacy research."&lt;SEP&gt;"Esposito K is a researcher and author involved in the study of insulin and GLP-1 receptor therapies for managing type 2 diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;GIUGLIANO D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Giugliano D contributes to research on combination therapy using insulin and GLP-1 receptor agonists in type 2 diabetes."&lt;SEP&gt;"Giugliano D is involved in comprehensive studies on diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MANNUCCI E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Mannucci E is a researcher involved in the study of diabetes treatment specifically focusing on insulin analogues."&lt;SEP&gt;"Mannucci E is involved in a meta-analysis comparing short-acting insulin analogues versus regular human insulin in diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;CAIULO C&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Caiulo C is a researcher contributing to meta-analyses on the efficacy and safety of diabetes treatments."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;NALETTO L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Naletto L is a researcher involved in studies regarding basal and prandial insulin analogues."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MADAMA G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Madama G participates in the research on treatments for type 2 diabetes focusing on network meta-analyses."</data>
      <data key="d2">chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;MONAMI M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Monami M is a contributing author to the meta-analysis on the efficacy of short-acting insulin analogues in type 2 diabetes."&lt;SEP&gt;"Monami M is involved in studies analyzing various insulin analogues for effective diabetes management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a&lt;SEP&gt;chunk-88de8001dff76be35895f3e67690af46</data>
    </node>
    <node id="&quot;COWART K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cowart K is an author of a clinical diabetes article discussing overbasalization and treatment intensification beyond basal insulin."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;CASTELLANA M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Castellana M is a co-author involved in the meta-analysis of GLP-1 receptor agonists added to insulin in type 2 diabetes therapy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;CIGNARELLI A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cignarelli A is a contributing author to the research on GLP-1 receptor agonists and insulin therapy for type 2 diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;BRESCIA F&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Brescia F is an author in the study comparing GLP-1 receptor agonists in the management of type 2 diabetes with insulin."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;LAVIOLA L&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Laviola L collaborates on research investigating the addition of GLP-1 receptor agonists to insulin therapy in diabetes care."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;RODBARD HW&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Rodbard HW participates in research on treatment intensification with insulin aspart boluses compared to basal-bolus therapy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;VISCO VE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Visco VE is a co-author contributing to a clinical trial comparing insulin aspart boluses with basal-bolus therapy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;ANDERSEN H&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Andersen H is involved in clinical research comparing stepwise addition of insulin aspart boluses to full basal-bolus therapy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;HIORT LC&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hiort LC is a researcher participating in a randomized clinical trial on insulin treatment strategies for diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;SHU DHW&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Shu DHW co-authors a study on treatment intensification using insulin aspart boluses in diabetes care."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;MCCALL AL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"McCall AL is an author of an article focusing on insulin therapy and the challenges of hypoglycemia management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;MARCHIONNI N&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Marchionni N is a co-author of a study analyzing the effects of short-acting insulin analogues in diabetes treatment."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;HELLER S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Heller S participates in a meta-analysis of insulin aspart and regular human insulin used in basal-bolus regimens for diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;BODE B&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bode B is an author involved in a comparative analysis of insulin aspart against regular human insulin in diabetes therapy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;KOZLOVSKI P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kozlovski P collaborates on research examining the comparative effectiveness of insulin aspart in diabetes management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;SVENDSEN AL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Svendsen AL contributes to a study on insulin aspart versus regular insulin in a basal-bolus regimen for diabetes treatment."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;DE LA PEÑA A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"de la Peña A is an author involved in pharmacodynamic studies of various insulin forms including U-500 and U-100 insulins."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;RIDDLE M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Riddle M contributes to research on sustained glycaemic control with different insulin formulations in type 2 diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;MORROW LA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Morrow LA is a researcher authoring pharmacokinetic and pharmacodynamic studies on insulin formulations."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;YKI-JÄRVINEN H&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Yki-Järvinen H is a researcher and author involved in studies comparing insulin glargine formulations and their impacts on glycaemic control."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;WARREN ML&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Warren ML is an author studying the efficacy and safety of high-dose insulin regimens for severely insulin-resistant patients."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;WANG T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Wang T contributes to research on insulin dosing regimens and their impacts on treatment outcomes for type 2 diabetes patients."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;MORWICK TM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Morwick TM is involved in studies examining insulin dosage adjustments and their impact on glycemic management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;JACKSON JA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jackson JA researches insulin dosage titration and its efficacy in insulin-resistant diabetes patients."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;GENTILE S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Gentile S is an author involved in a trial comparing different lispro insulin formulations and their effect on treatment adherence in diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;FUSCO A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Fusco A contributes to a study focused on lispro insulin formulations and their safety and efficacy in treatment adherence."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;COLARUSSO S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Colarusso S is involved in research comparing lispro insulin formulations and their impact on patient preference and adherence."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;HOOD RC&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hood RC is a researcher contributing to studies on insulin dosage effects in severely insulin-resistant patients."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;BECKER RHA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Becker RHA is an author exploring the activity profiles of new insulin formulations and their control of diabetes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;DAHMEN R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Dahmen R engages in research comparing different formulations of insulin for effectiveness in diabetes care."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;BERGMANN K&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bergmann K participates in research on the glycemic control offered by newer insulin formulations in diabetic patients."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;LEHMANN A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lehmann A is involved in studies assessing the glycemic control of various insulin glargine concentrations."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;JAX T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Jax T contributes to research on basal insulin formulations and their effectiveness in glycemic management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;HEISE T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Heise T researches insulin glargine formulations and their effect on diabetes management."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;BERGENSTAL R&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Bergenstal R is an author focusing on glucose control and hypoglycemia in studies of new insulin glargine formulations."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;ZIEMEN M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ziemen M contributes to clinical trials on insulin glargine formulations and their impacts on treatment outcomes."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;SEGER M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Seger M is a researcher studying pharmaceutics of insulin lispro formulations in diabetes care."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;SOON D&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Soon D participates in research comparing the pharmacodynamics of different insulin lispro formulations."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;KORSATKO S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Korsatko S is involved in clinical drug investigations focused on ultra-long-acting insulin formulations."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;DELLER S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Deller S collaborates on research comparing ultra-long-acting insulin formulations and their efficacy."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;KOEHLER G&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Koehler G is a researcher contributing to studies on insulin formulation pharmacokinetics."</data>
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
    </node>
    <node id="&quot;AKTURK HK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Akturk HK is one of the authors involved in research on diabetes treatment, specifically focusing on the study of inhaled technosphere insulin for patients with type 1 diabetes."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;SNELL-BERGEON JK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Snell-Bergeon JK participates in diabetes research, contributing to studies comparing inhaled technosphere insulin with insulin aspart."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;REWERS A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Rewers A is a researcher engaged in diabetes studies, specifically evaluating the efficacy of inhaled technosphere insulin."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;HOOGWERF BJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hoogwerf BJ is a researcher contributing to trials comparing technosphere insulin with other insulin formulations in type 2 diabetes treatment."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;CENTERS FOR MEDICARE &amp; MEDICAID SERVICES&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Centers for Medicare &amp; Medicaid Services, a U.S. government agency, oversees healthcare programs including the Part D Senior Savings Model aiming to reduce drug costs."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;U.S. FOOD &amp; DRUG ADMINISTRATION&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"The U.S. Food &amp; Drug Administration is a federal agency that issued an alert regarding dosing errors with compounded semaglutide products."&lt;SEP&gt;"U.S. Food &amp; Drug Administration is a regulatory agency responsible for the integrity of drugs and food, providing alerts on drug shortages and safety warnings."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7&lt;SEP&gt;chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;LIBRARY OF CONGRESS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Library of Congress is a U.S. government institution that maintains records on legislation like the Inflation Reduction Act of 2022."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;INFLATION REDUCTION ACT OF 2022&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"The Inflation Reduction Act of 2022 is a legislative initiative aimed at addressing economic issues, with implications for healthcare costs."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;STATE INSULIN COPAY CAPS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"State Insulin Copay Caps refer to legislative measures designed to limit out-of-pocket expenses for insulin by capping copay amounts for diabetes patients."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;VALENTINE V&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Valentine V is involved in research on glucagon autoinjectors, focusing on their usability and validation in severe hypoglycemia scenarios."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;NEWSWANGER B&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Newswanger B contributes to studies on glucagon delivery methods, emphasizing differences between nasal and injectable glucagon in hypoglycemia rescue."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;PRESTRELSKI S&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Prestrelski S is engaged in research analyzing the performance of glucagon autoinjectors during hypoglycemic emergencies."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;ANDRE AD&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Andre AD is a researcher participating in studies seeking to improve the delivery and usability of glucagon delivery systems."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;GARIBALDI M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Garibaldi M is part of a team assessing human factors and usability of glucagon autoinjectors in simulated hypoglycemia situations."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;SETTLES JA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Settles JA is a researcher investigating the effectiveness of nasal versus injectable glucagon delivery in emergency hypoglycemia."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;GERETY GF&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Gerety GF is involved in studies comparing different glucagon delivery methods to determine efficacy in hypoglycemia rescue scenarios."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;SPAEPEN E&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Spaepen E participates in research focusing on glucagon delivery methods and their success rates in treating severe hypoglycemia."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;SUICO JG&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Suico JG contributes to studies on nasal glucagon delivery, highlighting advantages in simulated hypoglycemia emergencies."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;CHILD CJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Child CJ is a researcher studying nasal glucagon delivery effectiveness compared to injectable methods."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;HERMAN WH&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Herman WH is involved in research related to the economic impacts of diabetes care."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;MERATIVE&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Merative provides electronic access to Redbook, which contains drug pricing and cost data."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;DATA.MEDICAID.GOV&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Data.Medicaid.gov hosts the NADAC dataset, providing information on average drug acquisition costs in the U.S."</data>
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
    </node>
    <node id="&quot;RAF AR&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Raf AR is an individual who contributed to a study on the safety and risk assessment of online semaglutide purchases."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;MACKEY TK&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Mackey TK is an individual who contributed to a study on the safety and risk assessment of online semaglutide purchases."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;SCHMIDT J&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Schmidt J is an individual who contributed to a study on the safety and risk assessment of online semaglutide purchases."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;FDA ALERT ON SEMAGLUTIDE DOSING ERRORS&quot;">
      <data key="d0">"EVENT"</data>
      <data key="d1">"An FDA alert that informs healthcare providers, compounders, and patients about dosing errors associated with compounded injectable semaglutide products."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;GALLAGHER EJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Gallagher EJ is an individual involved in expert consensus recommendations on managing hyperglycemia associated with alpelisib."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;MOORE H&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Moore H is an individual involved in expert consensus recommendations on managing hyperglycemia associated with alpelisib."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;LACOUTURE ME&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Lacouture ME is an individual involved in expert consensus recommendations on managing hyperglycemia associated with alpelisib."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;GONCALVES MD&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Goncalves MD is an individual who contributed to research on the management of PI3K inhibitor-associated hyperglycemia."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;FAROOKI A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Farooki A is an individual who contributed to research on the management of PI3K inhibitor-associated hyperglycemia."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;CHEUNG Y-MM&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Cheung Y-MM is an individual involved in a targeted approach to managing hyperglycemia induced by PI3K/Akt/mTOR pathways."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;MCDONNELL M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"McDonnell M is an individual involved in a targeted approach to managing hyperglycemia induced by PI3K/Akt/mTOR pathways."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;HAMNVIK O-PR&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Hamnvik O-PR is an individual involved in a targeted approach to managing hyperglycemia induced by PI3K/Akt/mTOR pathways."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;ODE KL&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ode KL is involved in guidelines for the management of cystic fibrosis-related diabetes in children and adolescents."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;BALLMAN M&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Ballman M is involved in guidelines for the management of cystic fibrosis-related diabetes in children and adolescents."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;BATTEZZATI A&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Battezzati A is involved in guidelines for the management of cystic fibrosis-related diabetes in children and adolescents."</data>
      <data key="d2">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
    </node>
    <node id="&quot;BLAU JE&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Blau JE is an author of a study analyzing Ketoacidosis associated with SGLT2 inhibitor treatment."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;TELLA SH&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Tella SH is an author mentioned in a study on Ketoacidosis associated with SGLT2 inhibitor treatment."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;TAYLOR SI&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Taylor SI is an author involved in researching Ketoacidosis associated with SGLT2 inhibitor treatment."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;ROTHER KI&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Rother KI contributed to a study on Ketoacidosis associated with SGLT2 inhibitor treatment."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;KARAGIANNIS T&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Karagiannis T contributed to a comparative efficacy study on diabetes treatment."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;KAKOTRICHI P&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Kakotrichi P is among the authors of a network meta-analysis on diabetes medications."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;DAVIES MJ&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Davies MJ is an author of a consensus report on the management of hyperglycemia in type 2 diabetes."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d3">[{"level": 0, "cluster": 0}, {"level": 1, "cluster": 9}]</data>
    </node>
    <node id="&quot;D'ALESSIO DA&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"D'Alessio DA is involved in publishing a report on hyperglycemia management in diabetes."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;FRADKIN J&quot;">
      <data key="d0">"PERSON"</data>
      <data key="d1">"Fradkin J is mentioned as an author in a consensus report on diabetes management."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;DIABETES OBES METAB&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Diabetes Obes Metab is a medical journal publishing research on diabetes, obesity, and metabolism."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d3">[{"level": 0, "cluster": 2}, {"level": 1, "cluster": 12}]</data>
    </node>
    <node id="&quot;DIABETES METAB RES REV&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"Diabetes Metab Res Rev is a journal focused on publishing reviews related to diabetes and metabolism research."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;FAERS&quot;">
      <data key="d0">"ORGANIZATION"</data>
      <data key="d1">"FAERS, or the FDA Adverse Event Reporting System, collects data on adverse events and medication errors reported by healthcare professionals."</data>
      <data key="d2">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
    </node>
    <node id="&quot;INTENSIVE INSULIN THERAPY&quot;">
      <data key="d2">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d1">"Intensive insulin therapy can increase the risk of hypoglycemia due to more aggressive management of blood glucose levels."</data>
      <data key="d0">"UNKNOWN"</data>
      <data key="d3">[{"level": 0, "cluster": 6}]</data>
    </node>
    <node id="&quot;INSULIN ACCESS&quot;">
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d1">"Interchangeable Biosimilars could significantly affect insulin access by potentially lowering costs and impacting treatment choices."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;CSII&quot;">
      <data key="d2">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d1">"CSII is associated with reduced risks of severe hypoglycemia, offering a safer insulin therapy option compared to traditional injection methods."</data>
      <data key="d0">"UNKNOWN"</data>
      <data key="d3">[{"level": 0, "cluster": 6}]</data>
    </node>
    <node id="&quot;KIDNEY EFFECTS&quot;">
      <data key="d2">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d1">"GLP-1 receptor agonists show benefits for renal endpoints in clinical trials, driven by albuminuria outcomes."</data>
      <data key="d0">"UNKNOWN"</data>
      <data key="d3">[{"level": 0, "cluster": 3}, {"level": 1, "cluster": 16}]</data>
    </node>
    <node id="&quot;DIABETES&quot;">
      <data key="d2">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d1">"ICIs can lead to autoimmune toxicities, including diabetes, as a side effect of the drug's mechanism."</data>
      <data key="d0">"UNKNOWN"</data>
      <data key="d3">[{"level": 0, "cluster": 7}, {"level": 1, "cluster": 26}]</data>
    </node>
    <node id="&quot;GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS&quot;">
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d1">"Wright EE co-authored a systematic review analyzing the effectiveness of GLP-1 receptor agonists versus basal insulins."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;AWARD-2&quot;">
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d1">"Giorgino F was involved in the AWARD-2 trial comparing dulaglutide with insulin glargine."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;SUSTAIN 4&quot;">
      <data key="d2">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d1">"Aroda VR co-authored a trial studying once-weekly semaglutide and daily insulin glargine for diabetes management."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;GLP-1 RECEPTOR AGONISTS&quot;">
      <data key="d2">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d1">"Cowart K contributes to diabetes care literature where GLP-1 receptor agonists are discussed as part of treatment strategies."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;PART D SENIOR SAVINGS MODEL&quot;">
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d1">"Centers for Medicare &amp; Medicaid Services implements the Part D Senior Savings Model to reduce prescription drug costs for seniors."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <node id="&quot;FDA DRUG SHORTAGES&quot;">
      <data key="d2">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d1">"The U.S. Food &amp; Drug Administration monitors and addresses drug shortages as part of its regulatory duties."</data>
      <data key="d0">"UNKNOWN"</data>
    </node>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION (ADA)&quot;" target="&quot;ADA PROFESSIONAL PRACTICE COMMITTEE&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The ADA Professional Practice Committee is responsible for updating the standards set by the American Diabetes Association."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION (ADA)&quot;" target="&quot;DIABETES CARE 2025&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The ADA publishes the Diabetes Care 2025, which includes standards for pharmacologic approaches in glycemic treatment."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION (ADA)&quot;" target="&quot;EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)&quot;">
      <data key="d4">18.0</data>
      <data key="d5">"Both organizations collaborated on a consensus report about diabetes management."&lt;SEP&gt;"These two organizations collaborate to produce consensus reports on the management of type 1 diabetes in adults."</data>
      <data key="d6">chunk-de10a98e95ddf218ff3826e2a97bfe66&lt;SEP&gt;chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION (ADA)&quot;" target="&quot;DAVIES MJ&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Davies MJ co-authored a consensus report published by the ADA."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DIABETES CARE 2025&quot;" target="&quot;THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The findings from the DCCT are included in the Diabetes Care 2025 guidelines for intensive insulin therapy."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;THE DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)&quot;" target="&quot;A1C&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The DCCT showed that intensive therapy reduced A1C levels, improving long-term diabetes outcomes."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN THERAPY&quot;" target="&quot;CONTINUOUS GLUCOSE MONITORING&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Continuous Glucose Monitoring is a part of insulin therapy to improve glycemic outcomes for people with type 1 diabetes."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN THERAPY&quot;" target="&quot;METFORMIN&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"Insulin therapy may be added to metformin for glycemic management as the progressive nature of type 2 diabetes continues.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN THERAPY&quot;" target="&quot;INSULIN&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"Insulin is central to insulin therapy, crucial for achieving glycemic control in diabetes management.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HYPOGLYCEMIA&quot;" target="&quot;INTENSIVE INSULIN THERAPY&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Intensive insulin therapy can increase the risk of hypoglycemia due to more aggressive management of blood glucose levels."</data>
      <data key="d6">chunk-7283046ef7282a9ac26fc6d2d84e8351</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HYPOGLYCEMIA&quot;" target="&quot;CSII&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"CSII is associated with reduced risks of severe hypoglycemia, offering a safer insulin therapy option compared to traditional injection methods."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HYPOGLYCEMIA&quot;" target="&quot;HYPERGLYCEMIA&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both conditions represent extremes of blood glucose levels that need to be managed in diabetes treatment."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HYPOGLYCEMIA&quot;" target="&quot;SULFONYLUREAS&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"The use of sulfonylureas increases the risk of hypoglycemia, a concern for CKD patients.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;INSULIN PUMP THERAPY&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Insulin Pump Therapy is a treatment method used to manage Type 1 Diabetes through better insulin delivery and glucose management."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"CSII is a technology used to treat Type 1 Diabetes, providing benefits such as improved glucose control and reduced hypoglycemia risk."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;MULTIPLE DAILY INJECTIONS (MDI)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"MDI is a common treatment approach for managing Type 1 Diabetes, offering various insulin options for patients needing flexible dosing."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;BASAL INSULIN&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Basal insulin is crucial in the management of Type 1 Diabetes, providing a stable insulin background to control blood sugar levels day-to-day."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;RAPID-ACTING INSULIN ANALOGS (RAA)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"RAA are used in the management of Type 1 Diabetes for mealtime and correction doses, enabling better control of blood sugar fluctuations."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;INHALED HUMAN INSULIN&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Inhaled Human Insulin serves as a rapid-acting option to manage blood glucose levels in Type 1 Diabetes, offering an alternative to injectable insulins."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;INSULIN&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"Insulin is used as a primary treatment to manage glucose levels in individuals with type 1 diabetes."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;CONTINUOUS GLUCOSE MONITORING (CGM)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Continuous Glucose Monitoring improves glycemic outcomes and quality of life for individuals with type 1 diabetes."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;AUTOMATED INSULIN DELIVERY (AID)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Automated Insulin Delivery systems help achieve better glycemic control and reduce hypoglycemia in people with type 1 diabetes."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;PANCREAS TRANSPLANTATION&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Pancreas Transplantation is considered for patients with type 1 diabetes to help normalize glucose levels."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;ISLET TRANSPLANTATION&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Islet Transplantation offers an alternative approach to insulin therapy for managing type 1 diabetes."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;PRAMLINTIDE&quot;">
      <data key="d4">15.0</data>
      <data key="d5">"Pramlintide is used as an adjunct therapy for type 1 diabetes, demonstrating modest improvements in A1C and weight loss."&lt;SEP&gt;"Pramlintide is used as an adjunct treatment to insulin for managing type 1 diabetes."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;METFORMIN&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"Metformin is explored in adults with type 1 diabetes for its effects on weight and insulin dose, but does not sustainably improve A1C."</data>
      <data key="d6">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 1 DIABETES&quot;" target="&quot;LIRAGLUTIDE&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Liraglutide is studied in individuals with type 1 diabetes, showing benefits in A1C reduction and weight management."</data>
      <data key="d6">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN PUMP THERAPY&quot;" target="&quot;CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII)&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"Insulin Pump Therapy often involves CSII, utilizing a pump system to enhance the management of insulin dosing and glucose levels."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BASAL INSULIN&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Basal insulin is commonly prescribed to manage fasting blood glucose levels in people with type 2 diabetes."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BASAL INSULIN&quot;" target="&quot;GLP-1 RA&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"GLP-1 RA can be added to basal insulin to enhance glucose control and mitigate insulin therapy side effects."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BASAL INSULIN&quot;" target="&quot;PRANDIAL INSULIN&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Prandial insulin is often added to basal insulin therapy to handle postprandial glucose and complete insulin regimens."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BASAL INSULIN&quot;" target="&quot;PREMIXED INSULIN&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Basal insulin can be part of a switch to premixed insulin for simplified glucose management in diabetes therapy."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INHALED HUMAN INSULIN&quot;" target="&quot;FEV1 TESTING&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"FEV1 Testing is recommended for individuals intending to use Inhaled Human Insulin to ensure safety, particularly regarding lung function."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INHALED HUMAN INSULIN&quot;" target="&quot;DIABETES CARE&quot;">
      <data key="d4">5.0</data>
      <data key="d5">"Diabetes Care advises on the properties, usage, and safety considerations associated with Inhaled Human Insulin."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INHALED HUMAN INSULIN&quot;" target="&quot;CHRONIC LUNG DISEASE&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Inhaled Human Insulin is contraindicated for individuals with Chronic Lung Disease."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INTERCHANGEABLE BIOSIMILARS&quot;" target="&quot;INSULIN ACCESS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Interchangeable Biosimilars could significantly affect insulin access by potentially lowering costs and impacting treatment choices."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;QUALITY OF LIFE IMPROVEMENT&quot;" target="&quot;CSII&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"CSII contributes to Quality of Life Improvement for diabetes patients by reducing fear of hypoglycemia and distress associated with diabetes management."</data>
      <data key="d6">chunk-fb858d4e362841ba84f2a63603216725</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HOLT ET AL.&quot;" target="&quot;DONISLECEL-JUJN&quot;">
      <data key="d4">5.0</data>
      <data key="d5">"Holt et al. contribute to the research context within which Donislecel-jujn is discussed as a novel treatment."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DONISLECEL-JUJN&quot;" target="&quot;U.S.&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Donislecel-jujn is regulated as a cell therapy in the U.S., indicating the location's regulatory influence on medical treatments."</data>
      <data key="d6">chunk-939ace7c2694328428c1ff23160b9ec9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN&quot;" target="&quot;METFORMIN&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Insulin can be used alongside Metformin to enhance blood sugar control when Metformin alone is not sufficient"</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN&quot;" target="&quot;TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Insulin is used as part of the treatment plan for type 2 diabetes, especially in cases of severe hyperglycemia."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN&quot;" target="&quot;HYPERGLYCEMIA&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Insulin is often used to manage severe hyperglycemia, reducing high blood glucose levels."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INSULIN&quot;" target="&quot;INSULIN GLARGINE&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"Insulin Glargine is a form of insulin used for long-term blood sugar management in diabetes.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Metformin is commonly used to treat type 2 diabetes due to its efficacy in managing blood sugar levels and reducing related complications."</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;HYPERGLYCEMIA&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Metformin helps manage hyperglycemia in individuals with type 2 diabetes, maintaining blood sugar at target levels."</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;GASTROINTESTINAL INTOLERANCE&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Metformin can cause gastrointestinal intolerance as a side effect, which can be managed with dosage adjustments."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;LACTIC ACIDOSIS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"High levels of Metformin can lead to lactic acidosis, particularly in individuals with impaired kidney function."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;VITAMIN B12 DEFICIENCY&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"Metformin use is associated with an increased risk of vitamin B12 deficiency, necessitating monitoring."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;SGLT2I&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Metformin is often used in combination with SGLT2i in individuals with type 2 diabetes to enhance glucose-lowering efficacy without significant risk of hypoglycemia."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;GLP-1 RA&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Used together, these medications provide enhanced glucose control in individuals with type 2 diabetes while managing potential weight and cardiovascular impacts."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;MACE&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Metformin has a potential benefit in reducing the risk of major adverse cardiovascular events (MACE)."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;GRADE TRIAL&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"The GRADE trial examined metformin in combination with other diabetes medications, noting no prevention of CKD development."</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Metformin is commonly prescribed to manage blood sugar levels in those with type 2 diabetes, often as a first-line treatment."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;METFORMIN&quot;" target="&quot;ALPELISIB&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Metformin is used as a first-line treatment to manage hyperglycemia induced by Alpelisib."</data>
      <data key="d6">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;LIRAGLUTIDE&quot;" target="&quot;GLP-1 RA&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"Liraglutide is a GLP-1 receptor agonist that may provide benefits in glucose management for CKD patients.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SGLT2 INHIBITOR&quot;" target="&quot;TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"SGLT2 inhibitors are recommended for glycemic management and heart failure prevention in adults with type 2 diabetes."</data>
      <data key="d6">chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;TYPE 2 DIABETES&quot;">
      <data key="d4">27.0</data>
      <data key="d5">"GLP-1 RA is a treatment option for managing Type 2 Diabetes, particularly in lowering A1C levels and addressing cardiovascular risk factors."&lt;SEP&gt;"GLP-1 RA is recommended for managing type 2 diabetes due to its cardiovascular benefits."&lt;SEP&gt;"GLP-1 receptor agonists are suggested for glycemic management and cardiovascular event reduction in adults with type 2 diabetes."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470&lt;SEP&gt;chunk-f80055f0fffc1b47c489be87bbfcd205&lt;SEP&gt;chunk-457fb11fcd603727ca93eee3ec2d178d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;DPP-4 INHIBITORS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The concurrent use of GLP-1 RA and DPP-4 inhibitors is not recommended due to lack of additional benefits beyond GLP-1 RA alone."</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;SGLT2I&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"These two classes of drugs are often considered together for their complementary effects in managing type 2 diabetes, especially for added cardiovascular and kidney benefits."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;NPH&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both NPH and GLP-1 RA are options mentioned in the treatment plan for managing glucose levels in diabetes."</data>
      <data key="d6">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;SGLT2 INHIBITORS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both SGLT2 inhibitors and GLP-1 RAs are recommended for individuals with type 2 diabetes and CKD due to their cardiovascular and kidney benefits."</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RA&quot;" target="&quot;SEMAGLUTIDE&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Semaglutide, a GLP-1 RA, is noted for its beneficial effects on cardiovascular and kidney outcomes in CKD patients."</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HEART FAILURE&quot;" target="&quot;PIOGLITAZONE&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Pioglitazone has been linked to an increased risk of heart failure, advising its cautious use in susceptible individuals."</data>
      <data key="d6">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CKD&quot;" target="&quot;EGFR&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"eGFR is used to assess and monitor CKD, which informs treatment strategies for patients with diabetes."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MASLD&quot;" target="&quot;DSMES&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"DSMES supports individuals in managing conditions like MASLD through education and treatment adherence."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MASLD&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"People with type 2 diabetes are at high risk for developing MASLD due to obesity and metabolic factors."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MASH&quot;" target="&quot;TYPE 2 DIABETES&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Type 2 diabetes can increase the risk of developing MASH due to metabolic dysfunctions associated with diabetes."</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MASH&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"This group is highly susceptible to developing MASH as a progression of liver disease due to obesity and insulin resistance."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;HYPERGLYCEMIA&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Hyperglycemia is a common symptom of type 2 diabetes that needs to be managed to prevent complications."</data>
      <data key="d6">chunk-1e2674abf3db4f63fb100838e35f4bf9</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;SGLT2I&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"SGLT2i is used in managing type 2 diabetes for its demonstrated cardiovascular and kidney benefits."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;COMBINATION THERAPY&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Combination Therapy is crucial for managing type 2 diabetes due to the progressive nature of the disease."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;CVD&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Type 2 Diabetes treatment considerations include addressing cardiovascular disease risk factors as part of the treatment plan."</data>
      <data key="d6">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;CHRONIC KIDNEY DISEASE (CKD)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Type 2 Diabetes is a significant risk factor and potential cause for developing Chronic Kidney Disease."</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;ADOPT STUDY GROUP&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The ADOPT Study Group is focused on glycemic durability studies for type 2 diabetes treatments."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;GRADE STUDY RESEARCH GROUP&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The GRADE Study Research Group conducts research on glycemic outcomes in type 2 diabetes."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;EAGLE INVESTIGATORS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The EAGLE Investigators conducted a study comparing treatment options for type 2 diabetes."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;DUAL VIII&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"DUAL VIII trial studies insulin therapies in patients with type 2 diabetes."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;PIONEER 4 INVESTIGATORS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The PIONEER 4 trial investigates different drug effects in type 2 diabetes patients."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;TSAPAS A&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Tsapas A is involved in comparing glucose-lowering drugs for type 2 diabetes treatment options."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;BENNETT WL&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Bennett WL investigated the effectiveness and safety of diabetes medications for type 2 diabetes."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TYPE 2 DIABETES&quot;" target="&quot;NAUCK MA&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Nauck MA researched advanced drug combinations for diabetes treatment involving inhibitors and agonists."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DPP-4 INHIBITORS&quot;" target="&quot;SGLT2 INHIBITORS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both SGLT2 inhibitors and DPP-4 inhibitors are oral medications used to manage blood glucose in Type 2 diabetes."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DPP-4 INHIBITORS&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The DPP-4 inhibitors Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin are listed with AWP values regarding their wholesale pricing."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DPP-4 INHIBITORS&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The DPP-4 inhibitors category includes Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin, each having NADAC values."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ASCVD&quot;" target="&quot;CVD&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"ASCVD is a type of CVD, and understanding the relationship between these conditions is crucial for managing diabetes patients."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MEGLITINIDES&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The drugs Nateglinide and Repaglinide under Meglitinides are presented with their AWP values."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MEGLITINIDES&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Nateglinide and Repaglinide within the Meglitinides category have associated NADAC values, indicative of their pharmacy acquisition costs."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CARDIOVASCULAR AND KIDNEY RISK REDUCTION&quot;" target="&quot;ACE INHIBITORS (ACEI)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"ACE Inhibitors help reduce cardiovascular and kidney risks in diabetes management."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CARDIOVASCULAR AND KIDNEY RISK REDUCTION&quot;" target="&quot;ANGIOTENSIN RECEPTOR BLOCKERS (ARB)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"ARBs are used to lower cardiovascular and kidney risks in high-risk diabetes patients."</data>
      <data key="d6">chunk-452c662efbfd08e17b4e8bff2aee6470</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SEMAGLUTIDE&quot;" target="&quot;DULAGLUTIDE&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"These medications both belong to the GLP-1 RA class and are noted for their high efficacy in weight loss and glucose lowering."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SEMAGLUTIDE&quot;" target="&quot;TIRZEPATIDE&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both medications exhibit very high efficacy for weight loss in individuals with type 2 diabetes, suggesting strategic similarity in therapy goals."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SEMAGLUTIDE&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Semaglutide is used for effective glucose control and weight management in individuals with type 2 diabetes."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TIRZEPATIDE&quot;" target="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Tirzepatide is a favored medication for managing glucose levels and promoting weight loss in people with type 2 diabetes."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MACE&quot;" target="&quot;CVD&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"MACE outcomes are critical in evaluating treatments for CVD among diabetes patients to reduce cardiovascular risk."</data>
      <data key="d6">chunk-0328b0f6d78fc747e105127ef9112362</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MACE&quot;" target="&quot;SGLT2 INHIBITORS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"SGLT2 inhibitors provide benefits in reducing major adverse cardiovascular events as part of their cardiovascular effects."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MACE&quot;" target="&quot;GLP-1 RAS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"GLP-1 receptor agonists provide benefits in reducing major adverse cardiovascular events based on trial outcomes."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DAVIES ET AL.&quot;" target="&quot;NPH&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"The work of Davies et al. has been adapted to provide guidance on the use of NPH in diabetes treatment."</data>
      <data key="d6">chunk-f80055f0fffc1b47c489be87bbfcd205</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MI&quot;" target="&quot;SGLT2 INHIBITORS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"SGLT2 inhibitors help provide cardiovascular benefits and reduce risks associated with myocardial infarction events."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SGLT2 INHIBITORS&quot;" target="&quot;EMPAGLIFLOZIN&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"Empagliflozin is part of the SGLT2 inhibitors class, highlighting its role in CKD and cardiovascular benefit studies.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SGLT2 INHIBITORS&quot;" target="&quot;OBESITY&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"SGLT2 inhibitors may help in managing obesity and improving glucose levels in individuals with obesity and type 2 diabetes."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SGLT2 INHIBITORS&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"SGLT2 inhibitors such as Bexagliflozin, Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin are listed with their respective AWP values to denote wholesale pricing."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SGLT2 INHIBITORS&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The SGLT2 inhibitors category includes drugs with specified NADAC values to indicate pharmacy acquisition cost."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RAS&quot;" target="&quot;KIDNEY EFFECTS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"GLP-1 receptor agonists show benefits for renal endpoints in clinical trials, driven by albuminuria outcomes."</data>
      <data key="d6">chunk-ed8f01888129fdaf40fb2ff6fd23009f</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RAS&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The GLP-1 RAs including Dulaglutide, Exenatide, Liraglutide, and Semaglutide have their AWP explicitly mentioned."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLP-1 RAS&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"NADAC values for GLP-1 RAs such as Dulaglutide, Exenatide, Liraglutide, and Semaglutide represent pharmacy acquisition costs."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DUAL GIP AND GLP-1 RA&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Tirzepatide within this category is listed alongside its AWP, indicating cost to wholesale distributors."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DUAL GIP AND GLP-1 RA&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Tirzepatide in this class has a specific NADAC value that represents pharmacy acquisition pricing."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SITAGLIPTIN&quot;" target="&quot;CKD, CHRONIC KIDNEY DISEASE&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Sitagliptin dosing must be adjusted for patients with chronic kidney disease to ensure safety and effectiveness."</data>
      <data key="d6">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SAXAGLIPTIN&quot;" target="&quot;U.S. FOOD AND DRUG ADMINISTRATION&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The FDA provides regulatory guidance and warnings concerning the use of medications like saxagliptin due to potential risks."</data>
      <data key="d6">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ALOGLIPTIN&quot;" target="&quot;CKD, CHRONIC KIDNEY DISEASE&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Alogliptin's dosage requires adjustments based on kidney function to prevent adverse effects in CKD patients."</data>
      <data key="d6">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;U.S. FOOD AND DRUG ADMINISTRATION&quot;" target="&quot;METFORMIN USE IN TYPE 2 DIABETES MELLITUS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The FDA provides guidance and communications regarding the use of metformin, particularly related to safety and appropriate use conditions."</data>
      <data key="d6">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;FDA SPECIAL WARNING&quot;" target="&quot;SULFONYLUREAS (2ND GENERATION)&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The FDA has highlighted increased cardiovascular mortality risks associated with second-generation sulfonylureas, influencing their use in treatment."</data>
      <data key="d6">chunk-e85e48af3b3b13d2af30925d9354fcd0</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CHRONIC KIDNEY DISEASE (CKD)&quot;" target="&quot;EGFR (ESTIMATED GLOMERULAR FILTRATION RATE)&quot;">
      <data key="d4">1.0</data>
      <data key="d5">"eGFR is used to assess kidney function and guide treatment in CKD.</data>
      <data key="d6">chunk-8de930782e0a422078be5f8ebc18884b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;" target="&quot;INSULINS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Insulins are a primary treatment used to manage blood glucose levels in people with type 2 diabetes."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PEOPLE WITH TYPE 2 DIABETES&quot;" target="&quot;OBESITY&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Obesity is prevalent in over 90% of individuals with type 2 diabetes, affecting treatment and management strategies."</data>
      <data key="d6">chunk-407d253d798eb82be35aeed2955aca0a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;Α-GLUCOSIDASE INHIBITORS&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The medications Acarbose and Miglitol under α-Glucosidase inhibitors are associated with specific AWP values."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;Α-GLUCOSIDASE INHIBITORS&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Acarbose and Miglitol under α-Glucosidase inhibitors have NADAC values, indicating their acquisition cost by pharmacies."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PREMIXED INSULIN&quot;" target="&quot;INSULIN RESISTANCE&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"Premixed Insulin might be less suitable for individuals with Insulin Resistance who require larger, more flexible dosing options."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;U-500 REGULAR INSULIN&quot;" target="&quot;U-300 GLARGINE&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"Both are concentrated insulin preparations used to offer higher doses per volume, though they differ in concentration and pharmacokinetics."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;U-500 REGULAR INSULIN&quot;" target="&quot;DIABETES CARE&quot;">
      <data key="d4">5.0</data>
      <data key="d5">"Diabetes Care provides information on the use and characteristics of U-500 Regular Insulin, as part of managing insulin treatment for patients."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DIABETES CARE&quot;" target="&quot;HIGH-DEDUCTIBLE HEALTH PLANS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Diabetes Care discusses the impact of High-Deductible Health Plans on the affordability of diabetes treatments."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DIABETES CARE&quot;" target="&quot;DAVIES MJ&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Davies MJ co-authored a consensus report on hyperglycemia management published in the journal Diabetes Care."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;OUT-OF-POCKET COSTS&quot;" target="&quot;THREE MAJOR INSULIN MANUFACTURERS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The cap on insulin prices by Three Major Insulin Manufacturers aims to reduce Out-of-Pocket Costs for patients."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLUCAGON&quot;" target="&quot;CONTINUOUS INSULIN PUMPS&quot;">
      <data key="d4">5.0</data>
      <data key="d5">"Individuals using Continuous Insulin Pumps may also require Glucagon for managing hypoglycemia emergencies."</data>
      <data key="d6">chunk-970dc1eedc28722313163911ded94134</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GLUCAGON&quot;" target="&quot;FDA&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The FDA is responsible for approving glucagon and ensuring its safety and effectiveness for diabetes management."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INDIVIDUALS WITH DIABETES&quot;" target="&quot;CLINICIANS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Clinicians are responsible for monitoring and treating individuals with diabetes, ensuring appropriate glucagon prescriptions and management."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INDIVIDUALS WITH DIABETES&quot;" target="&quot;SCHOOL PERSONNEL&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"School personnel are part of the support network for individuals with diabetes, aware of how to assist during hypoglycemic events."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INDIVIDUALS WITH DIABETES&quot;" target="&quot;CAREGIVERS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Caregivers offer crucial support for individuals with diabetes by administering glucagon when needed."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INDIVIDUALS WITH DIABETES&quot;" target="&quot;HEALTHCARE TEAM&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The healthcare team collaborates to provide comprehensive care, addressing financial and medical needs of individuals with diabetes."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;INDIVIDUALS WITH DIABETES&quot;" target="&quot;PRECONCEPTION PLANNING&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Preconception planning helps individuals with diabetes achieve glycemic control and manage medication prior to pregnancy."</data>
      <data key="d6">chunk-9f27f49fbb657c452c4c12e087c59402</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SULFONYLUREAS (2ND GENERATION)&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The drugs under Sulfonylureas (2nd generation) are listed with specific AWP values, indicating their cost to wholesalers."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SULFONYLUREAS (2ND GENERATION)&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The drugs under Sulfonylureas (2nd generation) have specific NADAC values, representing their acquisition cost by pharmacies."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;THIAZOLIDINEDIONE&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The medication Pioglitazone under Thiazolidinedione is listed with an AWP, reflecting its wholesale pricing."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;THIAZOLIDINEDIONE&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Pioglitazone under Thiazolidinedione has a NADAC value, indicating its acquisition cost by pharmacies."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BILE ACID SEQUESTRANT&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The bile acid sequestrant Colesevelam is provided with AWP pricing information."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BILE ACID SEQUESTRANT&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Colesevelam within bile acid sequestrants has an associated NADAC value, indicating pharmacy acquisition cost."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DOPAMINE-2 AGONIST&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The dopamine-2 agonist Bromocriptine is listed with an AWP, indicating its pricing to wholesalers."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DOPAMINE-2 AGONIST&quot;" target="&quot;NADAC (NATIONAL AVERAGE DRUG ACQUISITION COST)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Bromocriptine within the dopamine-2 agonists category has a specific NADAC value to denote acquisition costs in pharmacies."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMYLIN MIMETIC&quot;" target="&quot;AWP (AVERAGE WHOLESALE PRICE)&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The amylin mimetic Pramlintide is detailed with an AWP value, indicative of its wholesale pricing."</data>
      <data key="d6">chunk-9e8b3929115236feb9883c10ca5e8cc5</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;IMMUNE CHECKPOINT INHIBITORS (ICIS)&quot;" target="&quot;DIABETES&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"ICIs can lead to autoimmune toxicities, including diabetes, as a side effect of the drug's mechanism."</data>
      <data key="d6">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ALPELISIB&quot;" target="&quot;DIABETES&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Alpelisib can cause hyperglycemia, a condition related to diabetes, due to its mechanism of inhibiting insulin action."</data>
      <data key="d6">chunk-80ef4eb2154fdce1f321d0bae2fea359</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)&quot;" target="&quot;EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) STUDY RESEARCH GROUP&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"These two organizations collaborate on research focused on type 1 diabetes, including mortality and complications studies."</data>
      <data key="d6">chunk-de10a98e95ddf218ff3826e2a97bfe66</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)&quot;" target="&quot;DAVIES MJ&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Davies MJ contributed to a consensus report involving the EASD."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;LANE W&quot;" target="&quot;SWITCH 1&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Lane W is an author involved in conducting the SWITCH 1 clinical trial."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BAILEY TS&quot;" target="&quot;SWITCH 1&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Bailey TS contributes to the SWITCH 1 study focused on insulin treatment."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GERETY G&quot;" target="&quot;SWITCH 1&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Gerety G is part of the team analyzing results from the SWITCH 1 trial."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SWITCH 1&quot;" target="&quot;JAMA 2017;318:33–44&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"The SWITCH 1 trial results are published in JAMA, showcasing its findings."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;HOME PD&quot;" target="&quot;EDITION 4&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Home PD is engaged in the EDITION 4 trial on different insulin formulations."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BERGENSTAL RM&quot;" target="&quot;EDITION 4&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Bergenstal RM collaborates on research for the EDITION 4 clinical trial."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;EDITION 4&quot;" target="&quot;DIABETES CARE 2015;38:2217–2225&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"The findings of EDITION 4 are detailed in a publication in Diabetes Care."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CENGIZ E&quot;" target="&quot;PEDIATR DIABETES 2022;23:1277–1296&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Cengiz E's work features in the publication on ISPAD guidelines."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION&quot;" target="&quot;THE TYPE 1 DIABETES SOURCEBOOK AUTHORS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The Sourcebook Authors are associated with guidelines provided by the American Diabetes Association."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;AMERICAN DIABETES ASSOCIATION&quot;" target="&quot;STATE INSULIN COPAY CAPS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The American Diabetes Association advocates for State Insulin Copay Caps to ensure affordable insulin access for diabetes patients."</data>
      <data key="d6">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PETERS AL&quot;" target="&quot;DIABETES CARE 2014;37:2034–2054&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Peters AL contributes to a significant publication about type 1 diabetes care."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DAFNE STUDY GROUP&quot;" target="&quot;BMJ 2002;325:746&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The DAFNE Study Group's research is published in the British Medical Journal."</data>
      <data key="d6">chunk-9c3cd62b8b53a4ccadfff9d9a3e78633</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DIRECNET STUDY GROUP&quot;" target="&quot;WASHINGTON&quot;">
      <data key="d4">6.0</data>
      <data key="d5">"The DirecNet Study Group possibly operates in collaboration or communication with Washington on diabetes studies."</data>
      <data key="d6">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;WASHINGTON&quot;" target="&quot;U.S. FOOD &amp; DRUG ADMINISTRATION&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The headquarters of the U.S. Food &amp; Drug Administration is located in Washington, from where the FDA Alert was issued."</data>
      <data key="d6">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;OPERATION: DULCE&quot;" target="&quot;NATIONAL LIBRARY OF MEDICINE&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Operation: Dulce and the National Library of Medicine are related through managing or accessing diabetes related studies and trials."</data>
      <data key="d6">chunk-22ef9e9a2b7a536cf2757bb291863fa8</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;NATIONAL LIBRARY OF MEDICINE&quot;" target="&quot;NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The National Center for Biotechnology Information is a part of the National Library of Medicine, facilitating access to biomedical and genomic data."</data>
      <data key="d6">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;NATIONAL LIBRARY OF MEDICINE&quot;" target="&quot;T1-DISCO&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The study T1-DISCO is cataloged and accessible through resources provided by the National Library of Medicine."</data>
      <data key="d6">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;NATIONAL LIBRARY OF MEDICINE&quot;" target="&quot;ADJUST-T1D&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"ADJUST-T1D is a trial documented and made accessible via the resources of the National Library of Medicine."</data>
      <data key="d6">chunk-61a0c6f969fef29c7e03e861b5fba80b</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ADOPT STUDY GROUP&quot;" target="&quot;KAHN SE&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Kahn SE contributed to the ADOPT study on glycemic durability in diabetes treatments."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PIONEER 4 INVESTIGATORS&quot;" target="&quot;HOFF ST&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Hoff ST is part of the PIONEER 4 Investigators group conducting a relevant clinical trial."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;PIONEER 4 INVESTIGATORS&quot;" target="&quot;PIONEER 4&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The PIONEER 4 Investigators lead the PIONEER 4 clinical trial evaluating diabetes treatments."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SUSTAIN 1&quot;" target="&quot;TSOUKAS GM&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Tsoukas GM is an author involved in the SUSTAIN 1 trial which evaluates a diabetes treatment."</data>
      <data key="d6">chunk-564b80b47eb36a6fed0e9a98e7f94a67</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;TSAPAS A&quot;" target="&quot;DIABETES OBES METAB&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Tsapas A published a systematic review on diabetes treatment in the journal Diabetes Obes Metab."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;KAHN SE&quot;" target="&quot;SURPASS-4 INVESTIGATORS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Kahn SE is associated with the SURPASS-4 Investigators as part of the clinical research team."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ARODA VR&quot;" target="&quot;SUSTAIN 4&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Aroda VR co-authored a trial studying once-weekly semaglutide and daily insulin glargine for diabetes management."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DEL PRATO S&quot;" target="&quot;SURPASS-4 INVESTIGATORS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Del Prato S is involved with the SURPASS-4 Investigators group in clinical research."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SURPASS-4 INVESTIGATORS&quot;" target="&quot;SURPASS-4&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"The SURPASS-4 Investigators are responsible for conducting the SURPASS-4 clinical trial."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SURPASS-4 INVESTIGATORS&quot;" target="&quot;PAVO I&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Pavo I is involved with the SURPASS-4 study group, which focuses on diabetes treatments."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;WRIGHT EE&quot;" target="&quot;GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Wright EE co-authored a systematic review analyzing the effectiveness of GLP-1 receptor agonists versus basal insulins."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;KWAN AYM&quot;" target="&quot;GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Kwan AYM contributed to the study comparing GLP-1 receptor agonists with basal insulins."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;KIM SC&quot;" target="&quot;GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Kim SC co-authored research on the efficacy of GLP-1 receptor agonists for diabetes management."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GIORGINO F&quot;" target="&quot;AWARD-2&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Giorgino F was involved in the AWARD-2 trial comparing dulaglutide with insulin glargine."</data>
      <data key="d6">chunk-438d4aab79b2532b245f5d6834c91d1d</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MCGUIRE DK&quot;" target="&quot;SHIH WJ&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both are researchers investigating the effects of SGLT2 inhibitors on cardiovascular and kidney outcomes."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;SHIH WJ&quot;" target="&quot;COSENTINO F&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both are researchers investigating the effects of SGLT2 inhibitors on cardiovascular and kidney outcomes."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;REYES-FARIAS CI&quot;" target="&quot;REATEGUI-DIAZ M&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both are involved in examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes with chronic kidney disease."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ROMANI-ROMANI F&quot;" target="&quot;PROKOP L&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both are involved in examining the effects of SGLT2 inhibitors on cardiovascular and renal outcomes with chronic kidney disease."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;EMPA-KIDNEY COLLABORATIVE GROUP&quot;" target="&quot;CREDENCE TRIAL INVESTIGATORS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both are research groups studying kidney outcomes related to SGLT2 inhibitors in patients with diabetes."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;WEXLER DJ&quot;" target="&quot;GRADE RESEARCH GROUP&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Wexler DJ is part of the GRADE Research Group studying glucose-lowering medications."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;NEWSOME PN&quot;" target="&quot;NN9931-4296 INVESTIGATORS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Newsome PN is part of the NN9931-4296 Investigators focusing on semaglutide's effects."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BUCHHOLTZ K&quot;" target="&quot;NN9931-4296 INVESTIGATORS&quot;">
      <data key="d4">9.0</data>
      <data key="d5">"Buchholtz K is part of the NN9931-4296 Investigators focusing on semaglutide's effects."</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CUSI K&quot;" target="&quot;NN9931-4296 INVESTIGATORS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Cusi K is conducting research related to semaglutide's effects and is presumably linked to the study.</data>
      <data key="d6">chunk-284705997e11847b0e232c90fbde9937</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MAIORINO MI&quot;" target="&quot;CHIODINI P&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both Maiorino MI and Chiodini P co-author a study focusing on combination therapies for type 2 diabetes."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;ESPOSITO K&quot;" target="&quot;GIUGLIANO D&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"These two authors collaborated on a systematic review analyzing the combination of insulin and GLP-1 receptor agonists for diabetes care."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;COWART K&quot;" target="&quot;GLP-1 RECEPTOR AGONISTS&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Cowart K contributes to diabetes care literature where GLP-1 receptor agonists are discussed as part of treatment strategies."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;RODBARD HW&quot;" target="&quot;SHU DHW&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both are researchers contributing to a randomized trial comparing stepwise insulin aspart boluses with full basal-bolus therapy for diabetes."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;DE LA PEÑA A&quot;" target="&quot;RIDDLE M&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both authors work in a field focusing on insulin formulation comparisons, contributing to clinical diabetes care literature."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;RIDDLE M&quot;" target="&quot;YKI-JÄRVINEN H&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Riddle M and Yki-Järvinen H co-author research on the effectiveness of different insulin glargine formulations for type 2 diabetes."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;YKI-JÄRVINEN H&quot;" target="&quot;BERGENSTAL R&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both authors collaborated on studies comparing insulin glargine formulations and their impact on glucose control and hypoglycemia."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;WANG T&quot;" target="&quot;JACKSON JA&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Jackson JA and Wang T collaborated on research about insulin dosing and its efficacy and safety for insulin-resistant diabetic patients."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;GENTILE S&quot;" target="&quot;COLARUSSO S&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"Both authors are involved in comparative trials on lispro insulin formulations and their influence on treatment adherence."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BECKER RHA&quot;" target="&quot;DAHMEN R&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Together, they engage in research comparing the activity profiles of newer insulin glargine formulations in diabetes care."</data>
      <data key="d6">chunk-d57cf2036a70b1737fea69be6857546a</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;CENTERS FOR MEDICARE &amp; MEDICAID SERVICES&quot;" target="&quot;PART D SENIOR SAVINGS MODEL&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Centers for Medicare &amp; Medicaid Services implements the Part D Senior Savings Model to reduce prescription drug costs for seniors."</data>
      <data key="d6">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;U.S. FOOD &amp; DRUG ADMINISTRATION&quot;" target="&quot;FDA DRUG SHORTAGES&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"The U.S. Food &amp; Drug Administration monitors and addresses drug shortages as part of its regulatory duties."</data>
      <data key="d6">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;U.S. FOOD &amp; DRUG ADMINISTRATION&quot;" target="&quot;FDA ALERT ON SEMAGLUTIDE DOSING ERRORS&quot;">
      <data key="d4">10.0</data>
      <data key="d5">"The U.S. Food &amp; Drug Administration issued the FDA Alert on Semaglutide Dosing Errors to inform of potential risks."</data>
      <data key="d6">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;LIBRARY OF CONGRESS&quot;" target="&quot;INFLATION REDUCTION ACT OF 2022&quot;">
      <data key="d4">7.0</data>
      <data key="d5">"The Library of Congress records information about the Inflation Reduction Act of 2022, a significant legislative event."</data>
      <data key="d6">chunk-e2df008d2a8499535cbcfdd7d4280ef7</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;RAF AR&quot;" target="&quot;MACKEY TK&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both Raf AR and Mackey TK are co-authors of a study on the safety and risk of online semaglutide purchases."</data>
      <data key="d6">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;RAF AR&quot;" target="&quot;SCHMIDT J&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both Raf AR and Schmidt J are co-authors of a study on the safety and risk of online semaglutide purchases."</data>
      <data key="d6">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;MACKEY TK&quot;" target="&quot;SCHMIDT J&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both Mackey TK and Schmidt J are co-authors of a study on the safety and risk of online semaglutide purchases."</data>
      <data key="d6">chunk-f7bde176b4a6e3dc2868550f094599a4</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BLAU JE&quot;" target="&quot;TELLA SH&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Blau JE and Tella SH collaborated on a study related to SGLT2 inhibitors and Ketoacidosis."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BLAU JE&quot;" target="&quot;TAYLOR SI&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Blau JE and Taylor SI were co-authors of research concerning SGLT2 inhibitors and Ketoacidosis."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BLAU JE&quot;" target="&quot;ROTHER KI&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Both Blau JE and Rother KI participated in a study about Ketoacidosis associated with SGLT2 inhibition."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BLAU JE&quot;" target="&quot;DIABETES METAB RES REV&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Blau JE published a study in the journal Diabetes Metab Res Rev on Ketoacidosis related to SGLT2 inhibitors."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
    <edge source="&quot;BLAU JE&quot;" target="&quot;FAERS&quot;">
      <data key="d4">8.0</data>
      <data key="d5">"Blau JE utilized FAERS data in their analysis of Ketoacidosis and SGLT2 inhibitors."</data>
      <data key="d6">chunk-4897d32a01ffeb7a8d01e64f36b6aa77</data>
      <data key="d7">1</data>
    </edge>
  </graph>
</graphml>
